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Background: There is increasing preclinical and clinical evidence that inhibition of the 
PI3K/mTOR pathway can improve the efficacy of endocrine treatment and overcome 
resistance, but patient stratification remains challenging due to the complex nature 
of the pathway which is characterised by multiple regulatory nodes and extensive 
crosstalk with other signalling pathways. Preoperative window studies are a 
validated clinical trial strategy to evaluate the impact of targeted therapies alongside 
endocrine agents in patients with early ER-positive breast cancer using the nuclear 
proliferation marker Ki67 as a surrogate endpoint of treatment benefit. The 
OPPORTUNE trial was designed to assess whether addition of the PI3K inhibitor 
Pictilisib can increase the anti-tumour effects of two-week preoperative anastrozole 
treatment in ER-positive breast cancer. 
Aims: The 3 aims of this project were to  
1. evaluate changes in tumour cell proliferation (by Ki67 expression pre and 
post-treatment) and apoptosis (by Caspase 3 expression) between patients 
treated with endocrine therapy alone and those treated with PI3K inhibitor 
Pictilisib plus Anastrozole.  
2. characterise the subgroup of patients that derives the maximum benefit of 
addition of pictilisib with a focusing on the activation status of the PI3K 
pathway, using targeted next generation sequencing and gene expression 
analysis, and   




Results: We demonstrated that adding pictilisib to anastrozole significantly increased 
the anti-proliferative response compared anastrozole alone as measured by 
suppression of Ki67 expression. The rate of apoptosis however was low and there 
was no clear evidence of a treatment-associated increase in apoptosis.  
When characterising the subgroup of patients that derives the maximum benefit of 
the addition of pictilisib, NGS identified patients with and without activating PIK3CA 
mutations but found no correlation between overall PIK3CA mutation status and 
added benefit of pictilisib. Our results suggested possible differences between helical 
and kinase domain PIK3CA mutations as patients with helical domain but not kinase 
domain mutations demonstrated a substantial benefit from pictilisib. Further 
assessment of PI3K pathway activation demonstrated an inverse association of a 
previously established PI3K inhibition gene signature with treatment response to 
anastrozole, suggesting this signature might be useful for selecting patients with 
partial endocrine resistance who might benefit from the addition of pictilisib. PAM50 
analysis demonstrated that patients with Luminal B tumours but not patients with 
Luminal A tumours derive a benefit from PI3K inhibition.  
The third aim of this project was to investigate treatment-associated changes in gene 
expression and protein expression and phosphorylation in the tumour and stroma. 
Using RNA and protein analysis, we were able to identify down-regulation of ER-
mediated transcription and cell cycle progression, but found no differences in the 
expression of ER target genes between both study arms, suggesting that the 
preclinically observed induction of ER target genes by PI3K inhibition is not relevant 
in the context of combined endocrine and PI3K inhibitor therapy. Surprisingly, there 
 
 
was no discernible differences between both groups in the expression and 
phosphorylation of PI3K downstream targets Phospho-AKT, pS6 and p4E-BP1.  
Gene expression analysis furthermore demonstrated that short-term treatment with 
pictilisib and/or anastrozole has a modest impact on the tumour immune 
microenvironment but the potential clinical implications remain to be determined.  
Conclusions: In summary, we were able to demonstrate that addition of the PI3K 
inhibitor pictilisib significantly increases the anti-proliferative response to 
anastrozole in ER-positive early breast cancers. By characterising PI3K activation and 
gene expression subtypes, we provided important information on the subgroup of 
patients who might benefit most from combined therapy which should guide optimal 
patient selection for future trials. 
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Chapter 1 Introduction 
 
1     Biology of Breast Cancer  
Breast cancer remains the most common malignancy affecting women in Europe or 
North America, corresponding to an age-corrected annual incidence of 100 to 120 
per 100000 females. Oestrogen and the oestrogen receptor (ER) play an important 
role in the development and progression of breast cancers. Breast cancer is a 
complex disease and presents a multifactorial aetiology. There are a wide range of 
risk factors from age, lifestyle, and diet to family history and genetic and epigenetic 
alterations in the genome. The nature of the cancer significantly influences prognosis 
and risk of recurrence (“Breast cancer incidence (invasive) statistics | Cancer 
Research UK,” n.d.)  
The normal breast is made up of a system of branched epithelial tubes, called ducts, 
which connect the lobules to the nipple where milk is secreted. The lobules contain 
secretory units called acini. The ducts of the breast are lined by a single layer of 
epithelial cells, surrounded by a layer of myoepithelial cells or basal cells, which are 
encircled by a basement membrane made up of laminin and collagen. This whole 
structure is surrounded by connective tissue and embedded into adipose tissue (Ali 
and Coombes, 2002). Breast cancers arise from the mammary epithelium and most 
commonly the epithelial cells of the distal ducts or the lobules. Breast cancer 
development is thought to begin with a benign epithelial lesion characterised by 
abnormal structure of the breast duct or lobule. This evolves into atypical hyperplasia 
where an extra cell layer grows within the lumen. These cells grow and proliferate 
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into an early stage in situ carcinoma. This develops into invasive breast cancer with 
cells reaching towards the nearest blood vessels and then lymph vessels to cause 
metastatic spread (Hu et al., 2008; Mego et al., 2010).  
Breast cancer can be broadly divided into in situ carcinoma and invasive carcinoma. 
Invasive breast cancer describes a group of malignant cancers, which have invaded 
into the surrounding breast tissue and have the potential to metastasise. Histological 
classification is not sufficient to fully describe the heterogeneity of invasive breast 
cancers. However, advances in molecular understanding along with gene expression 
profiling has helped refine breast cancer classification. Such classification is especially 
relevant when considering the medical treatment for breast cancers.  
For many years, breast cancers have been divided into 3 subgroups; based on 
presence of the 2 hormone receptors (HR), ER and progesterone receptor (PR), and 
the human epidermal growth factor receptor 2 (HER2/neu) (Yersal and Barutca, 
2014):  
 HR-positive, HER2-negative breast cancer, which express ER and/or PR but 
are negative for HER2,  
 HER2-positive breast cancer, where HER2 is over-expressed or amplified, 
regardless of ER and/or PR expression, and  
 Triple Negative Breast cancer, which are negative for ER, PR and HER2. 
More recently, gene expression profiling has reshaped our understanding of breast 
cancer by defining four intrinsic molecular subtypes, including the two ER-positive 
subtypes luminal A and luminal B, as well as a HER2-enriched and a basal-like 
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subtype. This classification has significant clinical relevance especially with regards 
the luminal subtypes.  
The luminal subtypes share expression of the ER and/or PR and generally have a 
better outcome than the HER2 and basal-like subtypes (Glueck et al., 2013; Koboldt 
et al., 2012; Sorlie et al., 2003). Luminal A breast cancers account for approximately 
40% of breast cancers and are characterised by high ER-signalling and the absence of 
overexpression or amplification of HER2. Luminal A cancers are generally low-grade 
tumours with a relatively low proliferation rate, excellent response to endocrine 
therapy and a favourable prognosis (Voduc et al., 2010).  
Luminal B cancers, which correspond to approximately 20% of cases, tend to have 
lower ER and/or PR expression, expression of proliferation markers, and higher 
histologic grade, which correlates with a worse prognosis and higher tendency to 
relapse compared to Luminal A tumours (Ignatiadis and Sotiriou, 2013; Sorlie et al., 
2003). Luminal B cancers also exhibit partial endocrine resistance. Luminal A and 
Luminal B cancers should therefore be regarded as distinct entities with specific 
oncogenic drivers, rather than more proliferative varieties of the same tumour 
subtype. 
HER2+ represents 20-30% of all diagnosed breast cancers, and exhibit over 
expression of HER2, with under-expression of luminal-associated genes (Révillion et 
al., 1998). Basal-like tumours account for up to 15% of all breast cancers. These 
tumours primarily exhibit no expression of ER, PR or HER2, but are a highly 
heterogeneous sub-group of breast cancers (Sinn and Kreipe, 2013; Viale, 2012) and 
have been sub divided in up to 6 separate subtypes (Lehmann et al., 2011). The highly 
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diverse nature of breast cancer, and increasing understanding of molecular markers 
and genetic profiling, means subtyping and classification is subject to continuous 
changes and adjustments.  
2     HR-positive breast cancer 
The majority of breast cancers are HR-positive and endocrine therapy constitutes the 
key treatment for these patients (Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) et al., 2015). 
The ERs are members of the nuclear hormone–receptor superfamily which includes 
receptors for other steroid hormones, thyroid hormone, vitamin D, and retinoic acid. 
There are two different ERs, ER and ER, which are encoded by the two genes ESR1 
and ESR2 (Green et al., 1986; Kuiper et al., 1996). Whereas ER is clinically highly 
relevant for breast cancer, the function of ER remains still unclear.  
Classically, the ERs function as transcription factors in the nucleus when they are 
bound to their respective ligands (Figure 1). ERs contain several functional domains, 
including the DNA-binding domain, a dimerization domain, a ligand-binding domain 
and several transcription activating domains. After entering cells, the ligand 
oestradiol (E2) binds to the ER, leading to a conformational change of the receptor 
that facilitates dissociation of receptor-associated proteins such as heat-shock 
protein (HSP) 90, homo-dimerization and association with co-regulatory proteins, 
such as amplified in breast cancer 1 (AIB1), that regulate the transcription of 
oestrogen-responsive genes (McKenna et al., 1998; Osborne et al., 2001). The 
dimerised ER binds to small palindromic DNA motifs known as oestrogen response 
elements (EREs) in the promoters of oestrogen-response genes. Two distinct 
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activation domains, AF1 and AF2, have been shown to mediate the activity of the ER 
with transcriptional co-activators or co- repressors. Whilst AF2 is integral to the 
ligand-binding domain and therefore ligand-dependent transcription, AF1 activity is 
regulated by phosphorylation which can occur through multiple cellular kinases. Both 
AF1 and AF2 can activate transcription independently and/or act synergistically. In 
addition to the classical nuclear transcriptional regulation, non-classical regulation at 
non-ERE sites and non-genomic ER activity have been described, which can play a 
relevant role in endocrine resistance. 
 
Figure 1 Mode of action of oestradiol (Wakeling, 2000). After entering cells, E2 binds to the 
ER, leading to a conformational change of the receptor that facilitates homo-dimerization 
and association with co-regulatory proteins, that regulate the transcription of oestrogen-
responsive genes. The dimerised ER binds to the EREs in the promoters of oestrogen-
response genes to regulate target gene transcription. ER, Oestrogen receptor, E, Oestradiol, 
AF, activation function, ERE, oestrogen response element. 
The naturally occurring oestrogens 17-oestradiol (E2), which is the most abundant 
circulating form, oestrone (E), and oestriol (E3) are C18 steroids derived from 
cholesterol. In premenopausal women, oestradiol (E2) is synthesized primarily in the 
ovaries. Ovarian function and E2 synthesis are regulated by the pituitary 
gonadotropins, FSH and LH. Oestrone and E3 are primarily formed in the liver from 
E2. Additional sources of E2 synthesis are liver, fat tissue and muscles, which are the 
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main sources for the non- reproductive functions of E2 in postmenopausal women. 
In addition, breast tumours can also produce E2 which is one of the reasons that 
intra-tumoral concentrations of E2 can be more than 20-fold higher than those 
present in the plasma. 
3     Endocrine therapy for breast cancer 
There are several ways of blocking the effects of oestrogen in ER-positive breast 
cancer (Figure 2). The main endocrine treatments strategies are directed at  
 inhibiting the action of ER in breast tissue using selective ER modulators 
(SERMs) (such as tamoxifen), which bind to the ER competing with E2,  
 withdrawing oestrogen through aromatase inhibitors (AIs; such as 
anastrozole, exemestane) which block peripheral oestrogen synthesis, or by 
ovarian ablation, or 
 targeting ER for degradation with selective ER down regulators (SERDs; 
fulvestrant).  
SERMs and SERDs are also often classified as anti-oestrogens based on the fact that 
both types of agents directly bind to the ER. There are distinct differences in the 
mode of action between SERMs and SERDs. The SERMs inhibit AF2- but not AF1-
activation (Figure 3). Because the ER activity in breast cancers is mainly due to AF2, 
SERMs act as an antagonist in breast cancer. However, in other tissues such as the 
uterus, AF1 activity can be more significant, resulting in greater agonistic activity of 
tamoxifen. SERDs such as fulvestrant prevent activation of both AF1 and AF2 and also 
lead to increased degradation of the ER; SERDs are therefore anti-oestrogenic in all 




Figure 2 Strategies for endocrine therapy of breast cancer and main classes of hormone 
therapy. The main endocrine treatments strategies are directed at reducing the production 
of E2 or at blocking the effect of E2 at the ER. ER, Oestrogen receptor, E, Oestradiol, SERM, 
selective ER modulators; SERD, selective ER down regulators, T, Tamoxifen, ERE, oestrogen 
response element. 
 
Figure 3 Mode of action of SERMs such as tamoxifen and SERDs such as fulvestrant 
(Wakeling, 2000). After entering cells, Tamoxifen binds to the ER, leading to a 
conformational change of the receptor that allows homo-dimerization and altered 
association with co-regulatory proteins but inhibits AF2 (whilst retaining AF1-activation); 
Fulvestrant effectively stops homo-dimerization and association with co-regulatory 
proteins, thus blocking activation of both AF1 and AF2 and also leading to increased 
degradation of the ER. ER, Oestrogen receptor, E, Oestradiol, AF, activation function, ERE, 




Endocrine treatment is generally offered to all patients with ER-positive early breast 
cancer, and it is also the first treatment option to most women with hormone-
sensitive, HER2-negative metastatic breast cancer. This recommendation is based 
upon lower toxicity of endocrine treatment and often longer durations of response 
in this subset as compared with cytotoxic chemotherapy, with no difference in overall 
survival (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al., 2015). 
Endocrine therapy for early breast cancer: In early breast cancer, tamoxifen, alone or 
in combination with ovarian suppression, remains a standard for premenopausal 
patients, whereas AIs are now generally considered standard for postmenopausal 
women. This was based on a big meta- analysis carried out by the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) including individual data of >30,000 
postmenopausal women with ER-positive early breast cancer treated within 
randomised trials AI versus tamoxifen. Primary outcome measures used were any 
recurrence of breast cancer, breast cancer mortality, death without recurrence, and 
all-cause mortality. Results showed that AIs reduce the recurrence rates of breast 
cancer by about 30% compared to tamoxifen and the 10-year breast cancer mortality 
rates by about 15% (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et 
al., 2015). AIs are also increasingly used in premenopausal women but require 
combination with ovarian suppression in this group of patients in order to be active. 
Most of the experience with endocrine therapy is for 5 years. However, more 
recently, several trials have evaluated the benefit of Tamoxifen or AIs beyond 5 years 
of therapy, as well as the benefits of 5 years AI after either 2-3 years of Tamoxifen or 
after 5 years of Tamoxifen. Randomised trials have demonstrated increased overall 
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survival and distant disease-free survival (DFS), reduced breast cancer-specific 
mortality, a decreased risk of recurrence, and a decreased risk of contralateral breast 
cancer associated with extended endocrine therapy. This has to be seen in context 
with an increased risk of endometrial cancer (if continuing tamoxifen), hot flashes 
and other menopausal symptoms, deep vein thrombosis or pulmonary embolism 
(tamoxifen), ischemic heart disease (AI), osteopenia/osteoporosis (AI), and uterine 
cancer (tamoxifen). 
Endocrine therapy for metastatic breast cancer: In metastatic breast cancer, single 
agent endocrine therapy used to be the standard until recently, but is increasingly 
replaced by combination therapies, e.g. with CDK4/6 inhibitors, mTOR inhibitors or 
PI3K inhibitors (see below). 
In terms of single agent endocrine therapies, there is no universal standard for the 
optimal sequence. In patients who received adjuvant treatment with Tamoxifen, 
third generation AIs are often considered first line treatment of choice for metastatic 
disease as they have produced a significant survival advantage compared with 
tamoxifen, progestogens and non-specific AIs in randomised clinical studies (Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al., 2015). However, recent 
data from two randomised trials suggest that Fulvestrant might be slightly more 
effective than AIs in patients who have not received prior endocrine therapy. In the 
randomised phase 2 trial FIRST, patients treated with Fulvestrant had a significantly 
longer median overall survival of 54.1 months compared to 48.4 months in the AI 
treated arm (Ellis et al., 2015). This was confirmed in a subsequent randomised phase 
3 trial of fulvestrant versus anastrozole (FALCON trial), demonstrating a significantly 
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longer progression-free survival in the fulvestrant group than in the anastrozole 
group (hazard ratio [HR] 0·797, 95% CI 0·637–0·999, p=0·0486). The median 
progression-free survival was 16·6 months (95% CI 13·83–20·99) in the fulvestrant 
group versus 13·8 months (11·99–16·59) in the anastrozole group (Robertson et al., 
2016). 
Patients who progress on AIs can be considered for tamoxifen and/or Fulvestrant or 
for a steroidal AI if they received a non-steroidal AI (exemestane) in the previous line. 
Initial trials with fulvestrant failed to show a significant difference compared to 
exemestane or tamoxifen, but subsequent studies showed that higher doses of 
fulvestrant might increase the activity. 
  
4     Endocrine resistance and co-targeting of the PI3K pathway  
Despite the fact that the majority of patients with ER-positive breast cancer initially 
benefit from endocrine therapy, all patients with metastatic disease will eventually 
experience endocrine resistance. Endocrine resistance remains one of the most 
challenging clinical problems and substantial efforts of preclinical and clinical 
research is being directed at elucidating the processes of resistance.  
Multiple studies indicate that acquired resistance to endocrine therapy is a 
progressive, step-wise phenomenon which transforms breast cancer cells from an 
oestrogen-dependent phenotype that is responsive to endocrine therapy, to a non-
responsive phenotype, and eventually to an oestrogen-independent phenotype 
(Giuliano et al., 2011).  
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From a molecular point of view, two main categories of endocrine resistance can be 
differentiated, characterised by either altered ER signalling leading to ligand-
independent ER activation or an increase in alternative, hormone-independent 
mitogenic or survival pathways (Figure 4). There is substantial overlap between both 
categories mainly through phosphorylation of the ER and co-regulatory proteins 
through alternative intracellular signalling pathways, leading to constitutive, ligand-
independent ER activation (Johnston, 2015).   
In the past few years, several studies have revealed the presence of acquired 
mutations in ESR1 that confer ligand-independent and constitutive activation. Whilst 
ESR1 mutations are extremely rare in early breast cancer, they are commonly found 
in metastatic breast cancer with an increasing incidence over time, especially in AI-
treated patients, reaching up to 40% (Fribbens et al., 2018, 2016; Jeselsohn et al., 
2015; Robinson et al., 2013; Toy et al., 2013). These mutations tend to segregate 
around a ‘hotspot’ area within the ligand binding domain (LBD) of the ER, clustering 
between amino acids 534–538, though mutations at other positions including S463 
and E380 have also been described (Carlson et al., 1997; Li et al., 2013). Multiple lines 
of preclinical research demonstrate that these mutations are constitutively active 
conferring constitutive, ligand-independent activation. ER LBD mutations may thus 
account for acquired endocrine resistance in a proportion of patients with metastatic 
breast cancer, with the idea being that as a patient becomes exposed to more and 
more endocrine treatment, this selective pressure results in clonal expansion of 





Figure 4 Mechanisms of Endocrine Resistance. Endocrine resistance result from altered ER 
signalling via cross-phosphorylation, mutations in the LGB or changes in co-regulatory 
proteins, or through an increase in alternative, hormone-independent mitogenic or survival 
pathways. ER, Oestrogen receptor; AF, activation function, LBD, Ligand binding domain. 
 
Upregulation of intracellular proliferation and cell survival signalling pathways is 
widely considered a key resistance mechanism, leading to alternative, ER-
independent pathways for proliferation and survival. Such adaptive mechanisms can 
result from genetic or epigenetic changes within the tumour that drive hormone-
independent mitogenic pathways. The main pathways implicated in this process are 
CDK4/6-Cyclin D signalling and the PI3K/AKT/mTOR pathway. 
Since this MD project was started, therapeutic targeting the Cyclin-dependent kinase 
4/6 (CDK4/6) pathway has become a new standard for the treatment of ER-positive 
breast cancer. Three CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) are 
currently approved for the use in HR-positive, metastatic breast cancer, either in 
combination with AIs or with Fulvestrant. This was based on several randomized trials 
demonstrating consistently that the addition of CDK4/6 inhibitors to endocrine 
therapy substantially improves progression-free survival with HRs in the range of 
0.52-0.58 (Cristofanilli et al., 2016; Finn et al., 2016; Goetz et al., 2017; Hortobagyi et 
al., 2016b; Sledge et al., 2017; Turner et al., 2015). 
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Targeting the PI3K/AKT/mTOR pathway: In addition to the CDK4/6 pathway, 
targeting the PI3K/AKT/mTOR pathway remains a key therapeutic strategy. This is 
based on substantial preclinical and clinical evidence that aberrant signalling through 
the Phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
signalling pathway plays a critical role in endocrine resistance (Miller et al., 2011).  
The PI3K/AKT/mTOR pathway functions as a sensor of mitogen, energy and nutrient 
levels and is a central controller of cell growth and survival (Figure 5). The 
PI3K/AKT/mTOR pathway is highly conserved and generally tightly controlled. The 
PI3K is directly activated through trans-membrane receptors which trigger PI3K-
catalysed conversion of phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Binding of PIP3 to AKT at the 
plasma membrane leads to AKT activation and subsequent downstream activation of 
mTOR by phosphorylating and inactivating PRAS40 and TSC2. The mTOR kinase is the 
catalytic component of two distinct multiprotein complexes, mTORC1 and mTORC2, 
which are defined by their associated proteins. Both complexes have different 
cellular functions. mTORC1 activates p70S6K and 4EBP1, which in turn activate the 
ribosomal protein S6 and eIF4E, promoting protein synthesis and cellular 
proliferation. 
The PI3K/AKT/mTOR pathway is one of the most frequently activated pathways in 
human tumours. Aberrant PI3K pathway activation occurs in approximately 50% of 
ER-positive breast cancer, most commonly through activating mutations of the PI3K 
catalytic subunit (Bärlund et al., 2000; Bellacosa et al., 1995; Feilotter et al., 1999; 
Samuels et al., 2004). Approximately 40% of ER-positive breast cancer patients have 
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activating somatic mutations in PIK3CA, most frequently in the hotspots exons 9 and 
20 of PIK3CA, the gene that encodes the p110α isoform of PI3K (Baselga et al., 2017; 
Cancer Genome Atlas Network, 2012; Hortobagyi et al., 2016a). An additional 5-10% 
have loss of the negative regulator PTEN or activating mutations of AKT1. Additional 
pathway aberrations such as amplification or mutations of the effectors AKT1, AKT2, 
or PDK1, or of upstream receptor tyrosine kinases such as HER2, EGFR or FGFR1, or 
loss of the negative regulator INPP4B, have been described in ER-positive breast 
cancer, making breast cancer a rational target for PI3K inhibitors. 
 
 
Figure 5: PI3K-AKT-mTOR pathway. The PI3K is directly activated through trans-membrane 
receptors which trigger PI3K-catalysed conversion of phosphatidylinositol (3,4)-
bisphosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Binding of 
PIP3 to AKT at the plasma membrane leads to AKT activation and subsequent downstream 
activation of mTOR, promoting protein synthesis, cellular proliferation and survival. P, 
Phosphorylation. 
 
Activation of the PI3K pathway has been demonstrated to promote resistance to 
endocrine therapy and hormonal independence in ER-positive breast cancer models 
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(Miller et al., 2010, 2009; Shou et al., 2004). Proteomic and transcriptional profiling 
of human HR-positive tumours suggest that increased signalling through the 
PI3K/AKT/mTOR pathway is associated with lower ER levels and resistance to 
endocrine therapy (Creighton et al., 2010; Miller et al., 2010). Inhibition of the 
PI3K/mTOR pathway in non-clinical models has been shown to upregulate ER/PR 
expression (Creighton et al., 2010) and enhance the antitumor effect of letrozole 
(Boulay et al., 2005).  
There is increasing preclinical and clinical evidence that inhibition of the PI3K/mTOR 
pathway can improve the efficacy of endocrine treatment and overcome resistance 
(Baselga et al., 2012; Boulay et al., 2005; Crowder et al., 2009; Ghayad et al., 2010; 
Thorpe et al., 2014). Importantly, oestradiol can suppress apoptosis induced by PI3K 
inhibition in ER-positive breast cancer, suggesting that PI3K-dependent and 
oestradiol-dependent cell survival mechanisms are independent (Crowder et al., 
2009). Preclinical studies demonstrate additive/synergistic anticancer activity and in 
some cases synthetic lethality of PI3K, AKT and/or mTOR inhibition and oestrogen 
deprivation, providing a strong rationale for the combination of PI3K/mTOR 
inhibitors and endocrine therapy (Boulay et al., 2005). It has furthermore been shown 
that PIK3CA wild-type or mutant tumours equally benefit from combined 
PI3K/Akt/mTOR pathway inhibition and endocrine therapy, suggesting that eligibility 
in clinical trials should not be restricted by PIK3CA mutation status. This, combined 
with the association of therapeutic resistance with increased PI3K pathway signalling, 
suggests that inhibition of PI3K/Akt/mTOR signalling could have broad applications 




5     Clinical development of in inhibitors of the PI3K pathway in ER-
positive breast cancer 
The PI3K/Akt/mTOR has been targeted on several levels. Table 1 provides and 
overview on pivotal clinical trials of PI3K, mTOR or AKT inhibitors targeting in 
metastatic ER-positive breast cancer. 
In a first randomised phase 2 trial in postmenopausal women with ER positive 
metastatic breast cancer (MBC), the addition of the mTOR inhibitor everolimus to 
tamoxifen showed a significant improvement of the time to progression (8.6 months 
vs 4.5 months, p=0.02) and overall survival (median not reached vs 24.4 months, 
p=0.01) compared to Tamoxifen alone (Bachelot et al., 2012). This was confirmed in 
a subsequent phase 3 study, BOLERO -2, which showed that the addition of 
everolimus to exemestane more than doubled progression free survival (PFS) 
compared to single agent exemestane in MBC patients whose disease was refractory 
to previous AI therapy (median PFS was 6.9 months with everolimus vs 2.8 months 
with placebo (Baselga et al., 2012). Interestingly, the benefit of everolimus was 
demonstrated irrespective of the presence of activating PIK3CA mutations 
(Hortobagyi et al., 2016a). In a randomised phase II study of neoadjuvant treatment 
in patients with ER positive breast cancer, everolimus increased the efficacy of 
letrozole as measured by a decrease in Ki67 expression, and improved the clinical 
response rate (Baselga et al., 2009). 
In contrast to the everolimus studies, trials with the mTOR inhibitor temsirolimus 
failed to demonstrate a benefit. In the HORIZON trial, AI-naive MBC patients were 
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treated with the mTOR inhibitor temsirolimus in addition to letrozole. The trial failed 
to show an improvement in the primary end point PFS (median, 9 months; HR, 0.9; 
95% CI, 0.76 to 1.07; p=0.25); one of the possible explanations might be that 
PI3K/mTOR pathway activation may be more relevant in acquired resistance (Wolff 
et al., 2013). Similarly, the TORC1/2 inhibitor vistusertib failed to demonstrate a 
benefit when added to fulvestrant in MBC, possibly due to insufficient inhibition of 
TORC1 activity (Schmid et al., 2019). 
 
 
Table 1 Randomised trials of inhibitors of PI3K, AKT and/or mTOR in metastatic breast 
cancer. Eve, Everolimus; Exe, Exemestane, Tem, Temsirolimus; Alpe, Alpelisib; Tase, 
Taselisib; Capi, Capivasertib; Vist, Vistusertib pan PI3K, pan PI3K inhibitor; a-PI3K, alpha-




The initial MBC clinical development of PI3K inhibitors focused on pan-PI3K 
inhibitors. As preclinical data were inconclusive towards whether PIK3CA mutations 
are predictive of response or benefit with PI3K inhibitors, most pan-PI3K inhibitor 
trials included patients irrespective of their PIK3CA mutations status.  
In the randomised phase 2 FERGI study, which looked at the addition of the PI3- 
kinase inhibitor pictilisib to fulvestrant versus fulvestrant alone in patients with ER-
positive, AI-resistant MBC, addition of the pan PI3K inhibitor Pictilisib to fulvestrant 
failed to show a significant improvement in PFS. There was no association of potential 
treatment benefit of pictilisib with the presence of PIK3CA mutations (Krop et al., 
2016). A more recent phase 3 trial with the pan-PI3K-inhibitor buparlisib (BELLE2) 
(Pritchard et al., 2013) showed a small but significant difference in median PFS for 
the combination of buparlisib with fulvestrant (5 months versus 6.9 months, p 
<0.001) compared to the fulvestrant alone in MBC patients with previous AI therapy. 
A similar relative benefit was observed in the BELLE-3 trial, which included MBC 
patients after prior mTOR inhibitor therapy (Di Leo et al., 2018). 
As in FERGI, the presence of PIK3CA mutations in the primary tumour was not 
predictive in the BELLE studies for the benefit of the PI3K inhibitor. However, analysis 
of PIK3CA mutations from plasma-derived cell-free DNA (cfDNA) suggested an 
increased benefit of buparlisib in PIK3CA mutant tumours (7 months vs 3.2 months, 
p<0.001). This is somewhat surprising as several studies have demonstrated high 
concordance of PIK3CA mutations measured in primary tumours and subsequent 
cfDNA analysis. Despite the substantial pre-clinical activity, the results from these 
two randomised clinical trials of pan PI3K inhibitors have been relatively 
32 
 
disappointing, compared to the activity of everolimus. One of the potential 
explanations might lie in the substantial toxicity of pan PI3K inhibitors. Many patients 
in the FERGI and BELLE studies required dose reductions or discontinued treatment 
with the PI3K inhibitors due to toxicity, potentially limiting its efficacy. In the BELLE-
2 study for examples, up to 25% of the patients who received buparlisib experienced 
severe adverse events (Campone et al., 2018). 
Consequently, future evaluation of PI3K inhibition in endocrine resistant breast 
cancer is focusing on inhibitors with greater selectivity to improve tolerability. In 
particular, reduced inhibition of the β-isoform, which is believed to be a key 
determinant of treatment- associated toxicity, might bring some potential benefits. 
These α-specific, β-sparing inhibitors have been investigated in two randomised 
phase 3 trials (SOLAR1, SANDPIPER) (André et al., 2019; Baselga et al., 2018). Both 
trials focused on patients with PIK3CA mutations in ER-positive MBC patients with 
prior AI therapy. Whilst alpelisib demonstrated a significant benefit with the addition 
of fulvestrant (SOLAR1 trial), improving the median PFS from 5.7 months to 11 
months (HR, 0.65, p<0.001), taselisib failed to demonstrated a meaningful benefit in 
PFS despite showing with a small improvement of the median PFS from 5.4 months 
to 7.4 months (HR 0.7; p=0.0037). 
More recently, the AKT inhibitor Capivasertib has demonstrated promising activity in 
patients with ER-positive metastatic breast cancer (Jones et al., 2020). In the 
FAKTION trial, capivasertib did not just improve PFS but also suggested a possible 
benefit in overall survival, irrespective of PIK3CA mutations. The phase 3 




6     Short term preoperative window studies  
Short term preoperative studies (WOO), are a validated clinical trial strategy to 
provide a rapid and cost-effective way of assessing the impact of targeted therapies 
alongside endocrine agents in patients with early ER-positive breast cancer (Figure 
6). These studies provide access to tissue pre and post treatment for 
pharmacodynamic and correlative studies, providing critical insights into the 
mechanisms of how the investigative drug affects the tumour environment and the 
detection of important biomarkers that would aid in the selection of the optimal 
patient population. 
These trials use the 2-4-week gap between the initial diagnostic biopsy and definitive 
surgery to treat patients with endocrine therapy +/- additional new targeted 
treatments to directly assess the treatment effect on the cancer. As 2-4 weeks are 
generally too short to see a significant change in the size of the tumour, these trials 
rely on changes in tumour characteristics before and after treatment, with the 
nuclear proliferation marker Ki67 generally being used as an intermediate endpoint 
of treatment benefit (Dowsett et al., 2007, 2005; Ellis et al., 2008; Hadad et al., 2015; 
Macaskill et al., 2011; Polychronis et al., 2005). Multiple trials have shown that 
reduced Ki67 expression after two weeks of preoperative endocrine therapy is linked 
with response after 3-4 months of treatment and, more importantly, with improved 






Figure 6 A simplified view of a window-of-opportunity trial. Patients recruited to the trial 
are randomised into treatment or control arms and samples to assess effectiveness of 
treatment are collected prior and post administration of trial drug. Assessment of efficacy is 
carried out using surrogate markers. At the end, all patients receive standard of care. 
 
Access to tumour tissue before and after treatment also enables comprehensive 
analysis of biomarker changes, thus providing critical insights into the optimal patient 
population, biomarker responses and potential mechanisms of resistance. Although 
Ki67 measurements in preoperative window studies cannot replace the need for 
adjuvant trials with clinical endpoints, they can greatly aid in the selection or 
rejection of candidate approaches for phase III studies and in defining the most 
appropriate patient populations. Over recent years, the perioperative window 
setting of these studies together with the incorporation of primary biological 
endpoints has been established as a novel approach for breast cancer research. 
There is further testing of this hypothesis of improved molecular prognostication 
when conducted on tumours after short term endocrine treatment in the Peri-
operative Endocrine Treatment for Individualising Care (POETIC) trial (Robertson et 
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al., 2018). If in this trial expression of ki67 or other molecular markers are found to 
have clinically significant value for predicting recurrence – free survival, this would 
greatly impact future work requiring only minimal resources to deliver this type of 
predictive testing routinely (Dowsett et al., 2007). 
   
7     Rationale for the Opportune study  
Pictilisib is a novel, selective, small-molecule inhibitor of Class I PI3K being developed 
by Genentech as an anti-cancer therapeutic. It is a potent inhibitor of the kinase 
activity of recombinant human p110a/p85a, with mean IC50 values of 8.0 and 3.4 nM. 
Pictilisib is also equipotent for both H1047R and E545K p110a mutants and potently 
inhibits other members of the Class I PI3K family (p110b/p85a, p110d/p85a, and 
p110y), with IC50 values of <75 nM (scintillation proximity assay). It binds Classes II, 
III, and IV PI3K family members weakly, or not at all including DNA-dependent protein 
kinase (DNA-PK) and mTOR, suggesting that pictilisib is a pan-inhibitor of the Class I 
PI3K family members. 
At the time the OPPORTUNE trial was established, antitumor activity of Pictilisib had 
been observed in multiple mouse xenograft models, including breast, and lung 
cancer cell models. In addition, correlative downstream PD markers of PI3K activity 
such as phosphorylated AKT (pAKT), phosphorylated S6 (pS6), and phosphorylated 
PRAS40 (pPRAS40) were suppressed at doses that were consistent with efficacy in 
these xenograft models 
Gene expression signatures associated with PI3K activity demonstrated substantial 
overlap between mutant and wild type patients, suggesting other mechanisms aside 
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from mutational activation may drive signalling through the pathway (López-Knowles 
et al., 2014) and emphasising the challenges of patient stratification in a pathway 
characterised by multiple regulatory nodes and extensive crosstalk with other 
signalling networks (Miller et al., 2011). These data highlighted the need for 
comprehensive molecular profiling of ER-positive breast cancer in order to identify 
biomarkers of response to PI3K inhibitors and to characterise patients most likely to 
benefit from this therapy.  
The preoperative window study OPPORTUNE was therefore designed to assess 
whether addition of Pictilisib can increase the anti-tumour effects of anastrozole in 
ER-positive breast cancer and to perform a comprehensive analysis of the effects of 




Chapter 2 Research aims and hypotheses 
 
1     Establish the effect of the PI3K inhibitor pictilisib on tumour cell 
proliferation and apoptosis in patients with ER-positive breast cancer. 
Pictilisib has shown substantial preclinical activity in preclinical ER-positive models 
with activity against both PIK3CA mutant and wild type models. Preclinical data have 
demonstrated that E2 can suppress apoptosis induced by PI3K inhibition in ER-
positive breast cancer, suggesting independent PI3K- and E2-dependent cell survival 
mechanisms. Combination of endocrine therapy and PI3K inhibitors has furthermore 
demonstrated synthetic lethality with substantially increased apoptosis compared to 
single-agent therapy. The first aim of this project was to compare changes in tumour 
cell proliferation (as measured by Ki67 expression) and in tumour cell apoptosis (as 
measured by Caspase 3 expression) in pre and post-treatment tumour samples 
between patients treated with endocrine therapy alone and patients treated with 
the PI3K inhibitor Pictilisib plus Anastrozole. Given the correlation between 
proliferation and apoptosis, we also assessed the effect of study treatment on the 
growth index, defined as Ki67 expression divided by Caspase-3 expression. 
 
2     Evaluate the interaction between PI3K pathway activation and benefit 
from PI3K inhibition and the treatment effects of pictilisib in subgroups  
One of the key aims of this project was to identify possible patient subgroups that 
derive an increased benefit from adding pictilisib to endocrine therapy. As such, a 
main focus was set on evaluating the interaction between PI3K pathway activation 
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and treatment response. Although preclinical studies have shown that PIK3CA 
mutations result in up-regulation of the PI3K pathway and are predictive of sensitivity 
to PI3K inhibitors, their clinical significance is less clear. The PI3K pathway is a 
complex pathway with multiple nodes influencing and modulating pathway 
activation. Activating PIK3CA mutations have been shown to be associated with 
favourable tumour characteristics and improved outcome in ER-positive breast 
cancer (Loi et al. 2010; Sabine et al. 2014) and are also not predictive of response to 
endocrine treatment or mTOR-targeted therapies in ER-positive breast cancer 
(Hortobagyi et al. 2016; López-Knowles et al. 2014). One of the secondary aims of 
this project was therefore to assess the interaction between PIK3CA mutations, as 
determined by NGS, and response to anastrozole or the combination therapy. Since 
analysis of PIK3Ca mutations might be insufficient to establish actual pathway 
activation, we also evaluated two gene signatures (GS), which had been correlated in 
vitro with PI3KCA mutations and/or response to PI3K inhibitors. As it had been 
hypothesized that luminal B biology could be a determinant of suboptimal response 
to endocrine therapy alone and potentially therefore define a subgroup that might 
derive an increased benefit from combination therapy with pictilisib and anastrozole, 
we also studied the possible impact of a number of baseline characteristics that have 




3     Investigate treatment-associated changes in gene expression and 
protein expression and phosphorylation in the tumour and stroma 
Previous data suggested that single agent PI3K inhibition up-regulates expression of 
ER target genes. There is also substantial evidence that ER signalling and PI3K 
signalling can regulate the tumour microenvironment. We therefore investigated the 
treatment effects on ER target genes and on key proteins and genes involved in the 
PI3K pathway and cell cycle control using gene expression and RPPA analysis. 
Furthermore, we studied the impact of anastrozole and the combination therapy on 







Chapter 3 Methods 
1     Trial design 
OPPORTUNE is an open label, randomised phase 2 window trial, comparing 2- weeks 
of pre-operative treatment with anastrozole or anastrozole plus pictilisib (with 2:1 
randomisation favouring the combination) in untreated, postmenopausal patients 
with ER- positive, HER2-negative breast cancer (Figure 7).  
The study had the following primary aims:  
 Determine whether adding a PI3K‐inhibitor to pre‐operative endocrine 
treatment of ER-positive breast cancer patients increases the effects on 
tumour cell proliferation or apoptosis 
 Identify predictors of sensitivity to PI3K‐inhibition in order to characterize the 
patient population that benefits most from treatment with PI3K inhibitors, 
and 
 Study the effects of combined endocrine and PI3K‐inhibitor therapy on breast 
cancer biology 
Treatment was given for 15 days (+/-2 days) unless there was evidence of 
unacceptable toxicity or if the patient requested to be released. The effects of the 
study treatment were assessed on tumour tissue specimens taken at baseline and 
after 15 days (+/-2 days) of the study treatment. The biopsies after 15 days of 
treatment were taken during definitive surgery provided this was performed on day 
15 (+/- 2 days). Patients who did not have definitive surgery scheduled for day 15 (+/- 
2 days) were required to undergo a core biopsy on day 15 to assess the effect of the 
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study treatment and were advised to continue treatment with anastrozole until 
surgery. Patients in the anastrozole plus pictilisib arm received the last dose of 
pictilisib within 2-4 hours prior to surgery.  
Definitive surgery should be performed within 15 days from the start of the study 
treatment. Study treatment should be continued until surgery or biopsy.  To gain 
further insight in the activity of the pictilisib, changes in relevant biomarkers were 
assessed on tumour tissue specimen obtained during definitive surgery. In addition, 
the study assessed the relationship between the anticipated anti-tumour activity of 
the study treatment and biological characteristics of subjects’ tumour at baseline or 
at surgery.   
 
 
Figure 7: OPPORTUNE trial design. If patients meet the inclusion criteria, they will be 
randomised favourably to the combination arm. Patients participating in the trial consent 





Patient were enrolled at 10 centres in the UK. The trial was approved by the UK MHRA 
and the London City East Research Ethics Committee (11/LO/1559). The trial was 
manged by the coordinating trial office at Brighton and Sussex Medical school 
(BSMS). Patient data were collected through electronic case report forms (CRFs). All 
patient data were verified by the trial monitor from BSMS. Clinical data for this 
analysis were extracted from the database after the last patient had completed their 
treatment and data had been verified by the clinical monitor. All patients provided 
written informed consent. This trial is registered under ISRCTN26131497. 
Patients were eligible if postmenopausal (aged ≥55 years with amenorrhea for ≥one 
year, or aged <55 years with amenorrhea for ≥one year with oestradiol <20pg/mL, or 
prior bilateral oophorectomy) and had histologically diagnosed ER-positive, HER2-
negative, invasive breast cancer. ER positive was defined as ≥1% of tumour cells 
positive on immunohistochemistry or an immunohistochemistry score (Allred) of ≥3. 
All patients had operable breast cancer ≥1 cm in diameter, adequate haematological, 
hepatic, and renal function, a baseline fasting plasma glucose level of <7·8mmol/L 
and a WHO performance status of 0–2. Prior treatment for breast cancer or use of 
hormone replacement therapy was not permitted. Patients with inflammatory 
cancer or distant metastases were excluded. Additionally, patients with significant 
pulmonary dysfunction, cardiac disease or diabetes mellitus were excluded. 
Patients were randomly assigned (2:1, favouring the combination) to receive 
treatment with anastrozole or anastrozole plus pictilisib. Computer-generated 
permuted blocks were used, and stratification was by centre and histological grade, 
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as assessed on the diagnostic core biopsy. Participants and investigators were aware 
of assignment but the investigators who measured the biomarkers were blinded. 
Anastrozole was given at a dose of 1mg OD. Pictilisib was initially administered at 
340mg OD; from August 2012 onwards, the dose of pictilisib was reduced to 260mg 
OD following safety data from other studies indicating a lower rate of mucosal and 
skin toxicity at 260mg. Five evaluable patients received 340mg pictilisib; the 
remaining patients received 260mg. Study treatment was given for 14 days, followed 
by surgical resection, adjuvant chemotherapy, endocrine therapy, and radiotherapy 
as appropriate for each patient according to local practice guidelines. 
Patients were monitored for adverse events (AEs) and changes in laboratory values, 
electrocardiogram, and physical examination findings. 
The sample size was based on the two primary aims. A first analysis was planned for 
70 evaluable patients providing 80% power at the 5% significance level (one-sided) 
to detect an effect size of 0.77 between ANA and ANA+PIC. Effect size was defined 
as [MANA+PIC – MANA]/σpooled, where MANA+PIC and MANA are geometric mean Ki67 
suppression values and σpooled = √[(σANA+PIC² + σANA²)/2]. The study was also planned 
to detect a 20% difference in RKi67-Day15 and RΔKi67 response rates between arms. The 
proportion of responders in the combination group was assumed to be 60% under 
the null hypothesis and 80% under the alternative hypothesis; the test statistic used 
is the one-sided Z test with pooled variance, giving a power of 86%.  
The number of samples evaluable for each endpoint was dependent on the 
availability of sufficient material. The protocol specified the prioritisation for tissue 
analyses. The primary endpoint analysis for Ki67 was prioritised; a total of 136 
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patients were evaluable for this analysis. For the secondary endpoint Caspase-3, 108 
patients had evaluable sections pre and post treatment. Central PR and PTEN IHC 
review was successful in 132 and 115 patients, respectively. DNA for next generation 
sequencing analysis was available from the post-treatment tissue sample in 129 
patients. A total of 53 and 32 paired samples were available for NanoString and RPPA 
analysis, respectively.  
 
2     Tumour samples 
A minimum of two core-cut tumour biopsies (14-gauge) were taken at baseline and 
at the end of treatment. The last dose of study medication was required within 2-4 
hours before the end-of-treatment biopsy.  
Biopsies for histology were placed into 10% buffered formalin within 10 minutes of 
sampling and fixed for ≥6 hours before processing and embedding in paraffin wax. 
Snap frozen cores were placed in liquid nitrogen within 10 minutes.  
All tumour core biopsies were reviewed centrally at Guys Hospital London and 
scanned in; histological sections were assessed by H&E staining to facilitate macro-
dissection of carcinoma tissue for additional biomarker analyses. Slides were 
subsequently reviewed independently by Prof Sarah Pinder and Dr Louise Lim. 
 
3     Immunohistochemistry 
Immunohistochemistry (IHC) for Ki67, Caspase-3, PR and PTEN was performed and 
analysed centrally. IHC was performed on 3-4μm sections from the FFPE core 
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biopsies after heat mediated antigen retrieval. Antibodies for Ki67 [Clone 30-9, 
Ventana], cleaved Caspase-3 [Clone Asp175, Cell Signalling], and PTEN (Clone 138G6, 
Cell Signalling) were used. Sections were only scored for Ki67, Caspase-3 and PTEN if 
the initial H&E stained section showed invasive cancer with clearly identifiable 
malignant epithelial cells and/or invasive tumour. For the trial, Ki67 and Caspase-3 
IHC were recorded independently by two investigators, who were blinded as to 
treatment allocation and each other’s assessment (Prof Sarah Pinder, Louise Lim). 
Ki67 analysis: A minimum of 1,000 invasive cancer cells were counted for Ki67 
analysis; Ki67 was scored as the percentage of positively stained cells. A cut-off of 
14% was selected to define high and low baseline Ki67 expression (Macaskill et al., 
2011; Yerushalmi et al., 2010). Primary Ki67 analysis was based on estimating the 
mean Ki67 suppression in each group and the geometric mean ratio of proportional 
changes between groups. Secondary Ki67 analyses were geometric mean end-of-
treatment Ki67 expression, individual end-of-treatment anti-proliferative response 
(RKi67-Day15) defined as Ln(Ki67Day15) ≤2, and individual anti-proliferative response 
(RΔKi67) defined as a ≥50% fall in Ki67 expression (Maisonneuve et al., 2014; O’Brien 
et al., 2010). 
Caspase-3 analysis: For Caspase-3, at least 3,000 invasive cancer cells were assessed, 
if available. Caspase-3 analyses included geometric mean change in Caspase-3 
between day 15 and baseline and individual apoptotic response (RΔCasp3), defined as 
a ≥50% increase in Caspase-3 IHC. 
Progesterone receptor analysis: PR was assessed centrally and regarded as positive 
if Allred score was ≥3. 
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PTEN analysis: PTEN was classified as “positive” if any cytoplasmic and/or nuclear 
expression immunoreaction was observed in tumour cells and “negative” if no 
immune reactivity was observed, with the surrounding tissue microenvironment 
serving as a positive internal control. 
 
  
4     DNA/RNA extraction 
Following macro-dissection for tumour-enriched areas with >70% malignant tissue, 
DNA and RNA were simultaneously extracted from FFPE sections using Qiagen 
AllPrep DNA/RNA FFPE kit as per manufacturer’s instructions. FFPE sections in tube 
were dewaxed and rehydrated using xylene-based protocol, and DNA/RNA extracted 
in a column-based approach. Nucleic acids were quantified and checked for purity 
using a UV spectrophotometer (NanoDrop). 
 
5     Gene expression analysis  
RNA expression analysis of approximately 800 breast cancer-related genes using the 
nCounter platform (NanoString Technologies, Seattle, US). The samples from this 
study were serial sections from FFPE tissue used for Ki67 determination. RNA analysis 
was performed at Genentech, Inc., South San Francisco, CA, US. RNA (100ng) was 
hybridized overnight at 65°C according to the NanoString protocol. Samples were 
subsequently loaded onto the NanoString nCounter Prep Station and transcripts 
were counted using the NanoString nCounter Digital Analyzer at a FOV of 280. 
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Samples were normalized to housekeeping genes. PAM50 analysis of Luminal A and 
Luminal B subtypes was carried out as previously reported (Parker et al., 2009). Data 
were transferred back for integrated analysis. 
 
6     Next Generation Sequencing 
Analysis of mutations and copy number changes of PIK3CA and other key pathway 
components was assessed by targeted next generation sequencing using the 
Ampliseq Comprehensive Cancer panel assay with the Ampliseq Library Kit 2.0 
according to the manufacturer’s instructions (ion torrent, life technologies, US). NGS 
analysis was performed at the Centre for Personalized Nanomedicine at the 
Australian Institute for Bioengineering and Nanotechnology, University of 
Queensland, Australia. NGS analysis was supported by a grant from the National 
Breast Cancer Foundation (NBCF) of Australia (CG-12-07). 
Samples underwent 19 rounds of amplification and were barcoded using the Ion 
Xpress barcodes (Ion torrent, LifeTechnologies). Each pool was quantified post-
adaptor ligation by qPCR. Samples were pooled to provide 300x coverage. The Ion PI 
Template OT2 200 v3 Kit, P1 chip and Ion PI Sequencing 200 v3 Kit were used as per 
the manufacturers protocol. Variant calling used the Torrent variant Caller (v4.0-
r76860) set on Somatic PGM low stringency settings. Torrent Suite 4.0.2 was used for 
data processing, base-calling, and mapping. Data were transferred back for 




7     Reverse Phase Protein Arrays 
Reverse Phase Protein Arrays (RPPA) analysis of 55 targets focused on PI3K pathway 
signalling, ER signalling, alternative intracellular signalling and cell cycle regulation. 
RPPA analysis was performed at Theranostics Health, Inc., Gaithersburg, MD, USA. 
32 matched pairs of patient flash frozen samples were selected for this study. Whole 
slide lysates were prepared and approximately 6nl of protein were printed in 4 
replicates of glass backed nitrocellulose slides. Protein was printed at approximately 
2 concentrations, 0.5mg/ml or 0.25mg/ml. Slides were incubated with 55 different 
antibodies (see Appendix) and target specific signal was captured at 635nm. The 
amount of protein printed at each spot was measured using a Sypro Ruby Protein 
Blot Stain (Invitrogen: S11791), captured at 532nm. The total protein yield is used as 
a denominator for primary antibody signal, giving us a total protein normalised 
signal. All results presented use the total protein normalised signal fit on a LOESS 
algorithm. Data were transferred back for integrated analysis. 
 
8     Statistical Analysis 
The main study endpoints are listed in Table 2: 
 
Primary Objective Endpoints  
Determine the activity of the study 
treatment on tumour-cell 
proliferation 
 The difference in geometric mean change 
(post-pre) in Ki67 expression between two 
treatment groups  
 To explore further, this will also be measured 
in patients with and without PI3K mutations 
and/or loss of PTEN 
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Secondary objectives Endpoints 
Determine the activity of the study 
treatment on tumour-cell 
proliferation 
Secondary Ki67 analyses: 
 Geometric mean Ki67 expression at the end 
of study treatment (Mean Ki67post).  
 Individual end-of treatment anti-proliferative 
response (ResponseKi67-Post), defined as the 
natural logarithm of percentage Ki67 positive 
cells of less than 1 or 1-2 at the end of study 
treatment 
 Individual anti-proliferative response 
(ResponseΔKi67), defined as a ≥50% fall in Ki67 
expression over the course of the study 
treatment  
Determine the effects of the study 
treatment on tumour-cell apoptosis  
Changes in the Caspase3 assay between pre- and 
post-treatment tumour samples: 
 Geometric mean change in Caspase3 assay 
between end-of-treatment and pre-
treatment tumour samples (Mean Δ 
Caspase3).  
 Individual apoptotic response 
(ResponseΔCASPASE3), defined as a ≥50% 
increase in Caspase3 assay over the course 
of the study treatment 
 Individual end-of treatment apoptotic 
response (ResponseCaspase3-Post), defined as the 
natural logarithm of percentage Caspase3 
positive cells of less than 1 or 1-2 at the end 
of study treatment 
Tertiary/Exploratory objectives Endpoints 
Evaluate potential biomarkers that 
may help predict response to 
anastrozole and/or pictilisib 
Alterations in DNA and RNA, including mutational 
status, RNA expression levels, DNA copy number, 
and protein expression 
Explore the biologic effects of 
anastrozole and/or pictilisib on 
breast cancer and stromal cells and 
establish pharmacodynamic markers 
of anastrozole and/or pictilisib 
action 
Explore mechanisms of resistance 
Table 2 Study Objectives and Endpoints 
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Populations for analysis: All analyses for Ki67 and Caspase3 changes were performed 
on a per- protocol population, defined as all patients who completed two weeks of 
treatment and for whom tumour biopsy specimens were available for assessment of 
biological response. Patients excluded from the Per-Protocol-Population were 
replaced. 
Sample Size: The planned study size was 94 evaluable patients in the anastrozole plus 
pictilisib group and 47 evaluable patients in the anastrozole group, respectively, to 
provide 80% power to detect an effect size of 0.58 between Anastrozole and 
Anastrozole + Pictilisib at the 5% significance level. The effect size (ES) was defined 
as the treatment difference divided by the standard deviation, i.e. ES = [M1 - M2]/ σ 
pooled, where M1 and M2 are the mean values of the differences of proportional 
Ki67 changes and σpooled = σ [(σ 1²+ σ 2²)/2]. Taking Cohen´s standard interpretation 
of effect sizes into account, 0.5 is the lower limit of medium effect. An effect size of 
0.5 corresponds to 33% of non-overlap between the two treatment groups. The non-
centrality parameter δ is 2.83. Critical t is 1.98.  
Group sample sizes of 47 patients in the Anastrozole group and 94 in the Anastrozole 
+ pictilisib group also achieved 80% power to detect a difference between the group 
response rates of 20%. Response was defined as a 50% or higher fall in Ki67 
expression. The proportion of responders in the Anastrozole + pictilisib group was 
assumed to be 60% under the null hypothesis and 80% under the alternative 
hypothesis. The proportion in the Anastrozole group was assumed to be 60%. The 
test statistic used was the one-sided Z test with pooled variance. The significance 
level was 5.1%. If the difference between the group response rates was 25%, then 
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the sample size needed was 28+56=84. On the other hand, if the difference was 30%, 
then only 18+36=54 patients were sufficient to detect this difference.  
Individual end-of treatment anti-proliferative response (ResponseKi67-Post), defined 
as the natural logarithm of percentage Ki67 positive cells of less than 1 or 1-2 at the 
end of study treatment, was another endpoint under which required sample size 
might be slightly lower.  
Assuming that approximately 40% of patients have activating PI3KCA mutations or 
PTEN deletions, the study had 80% power at a 5% significance level to detect an ES 
of 0.8. 
Efficacy analysis: The main analysis of apoptosis and proliferation were from baseline 
to day 15 using non-parametric statistics to compare the log (surgical/Pre-treatment) 
scores. Additional analyses of apoptosis and proliferation were from day 15 to 
definitive surgery.  
Treatment comparisons were tested with and without adjustment for baseline 
prognostic factors. In the absence of major confounding factors, the latter were 
considered secondary endpoints.  
On the assumption of a log normal distribution, Ki67 values were log transformed 
before analysis of mean ΔKi67, mean Ki67post, and ResponseKi67-Post. If Ki67 is not 
normally distributed, nonparametric, distribution-free tests like Wilcoxon Signed-
Rank Test, Sign Test or Wilcoxon Mann-Whitney test can be applied. Ln(Ki67post) and 
ln(Ki67pre) were used to calculate the geometric means. 0.1 was be added to every 
untransformed Ki67 value to avoid the mathematical anomaly that arises because 
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the log of zero is minus infinity. As a consequence of the assumption of a lognormal 
distribution, ln(Ki67post)–ln(Ki67pre) was also normally distributed. This formula 
gives the proportional change, and as a result mean log proportional changes and CI 
can be calculated and displayed on their original scale by back transformation. Mean 
ΔKi67 and mean Ki67post were compared between groups by use of the t- test, and 
the proportional change within groups was analysed with the paired t- test. The 
proportional reduction was calculated as one minus the proportional change.  
Anti-proliferative response ResponseΔKi67 and end-of treatment anti-proliferative 
response ResponseKi67-Post were calculated in all evaluable patients. An estimate 
of the anti-proliferative response rates RRΔKi67 and end-of treatment anti-
proliferative response rates RRKi67-Post and 95% CIs (Clopper and Pearson, 1934) 
was calculated for each treatment arm. CIs for the difference in response rates 
(Berger and Boos, 1994; Santner and Snell, 1980) were calculated. The relative risk 
(treatment:control) was reported along with the associated 95% confidence interval 
based on logistic regression model. 
A similar analyses strategy was applied for Caspase3 endpoints. 
Changes in secondary outcomes from baseline to post treatment were analysed 
between treatment groups with the Wilcoxon Mann-Whitney test and within 
treatment groups with the Wilcoxon signed rank test. Associations between 
outcomes were investigated by use of the Spearman’s rank correlation coefficient. A 
comprehensive statistical-analysis plan was prepared before un-blinding of the data. 
Subgroup analysis:  The effects of the study treatment were assessed separately in 
patients with and without PI3K mutations and/or PTEN deletions, Luminal A and B 
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subtypes and patients with high (>14%) or low (≤14% baseline Ki67). Additional 
subgroups were defined by the exploratory biomarker analysis. 
Statistical analyses for the trial were performed by Dr Shah-Jalal Sharker, trial 
statistician at the Centre of Experimental Cancer Medicine at Queen Mary University 
London. 
 
9     Summary of individual contribution 
Dr Lim oversaw the collection and cleaning of the clinical data as well as the collection 
and processing of the tissue samples. Following staining and scanning of the FFPE 
sections at Prof Pinder’s laboratory, Dr Lim reviewed and scored all samples for Ki67 
and Caspase-3 expression. The results were documented in the trial data base 
together with the independent scoring by Prof Pinder. Dr Lim was responsible for 
macro-dissection of tissue samples and subsequent DNA and RNA extraction and 
quantification as outlined in the methods section. She coordinated analysis of RNA 
and DNA samples at NanoString Technologies laboratories (Seattle, US), Theranostics 
Health (Gaithersburg, MD, USA) and the University of Queensland (Brisbane, 
Australia), respectively. Dr Lim coordinated transfer and integration of the 
translational data sets and the clinical data sets and assisted Dr Shah-Jalal Sharker 




Chapter 4 Results  
1     Effect of Study Treatment on Tumour Cell Proliferation  
Between January 2012, and September 2015, 167 patients underwent randomization 
(Figure 8). 54 patients were assigned to anastrozole alone and 113 patients to 
anastrozole plus pictilisib. Two patients were excluded because of violations of key 
eligibility criteria. Another two patients withdrew trial consent prior to the start of 
their study treatment. Assessment of the treatment effects was possible for 136 
patients who successfully completed the protocol; 27 patients (8 in the anastrozole 
arm and 19 in the combination arm) had insufficient tissue for analysis. 
 
Figure 8: Trial consort diagram 
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Baseline distributions of patient and tumour characteristics were similar in the 
treatment arms (Table 3); 62% of tumours were classified as Luminal B according to 
PAM50 analysis and 63.2% according to baseline Ki67 analysis using a cut-off of 14%. 
58.8% of tumours were PIK3CA wildtype. There was a slightly higher number of 
patients with PR positive tumours in the combination group. 
 Anastrozole                  
alone 
(n = 46) 
Pictilisib plus Anastrozole 
(n = 90) 
Age (years)   
     Median (range) 66.9 (47.7-85.4) 64.1 (48.5-81.1) 
Tumour status   
     Grade 1 5 (10.9%) 13 (14.6%) 
     Grade 2 34 (73.9%) 62 (69.7%) 
     Grade 3  7 (15.2%) 14 (16.9%) 
PR status    
     Positive  33 (71.4%) 82 (91.1%) 
     Negative 11 (23.9%) 6 (6.7%) 
Molecular Subtype (PAM50)   
     Luminal A 6 (31.6%) 14 (41.2%) 
     Luminal B 13 (68.4%) 20 (58.8%) 
Ki67 (% positive tumour cells)   
     Mean (range) 23.0 (1.9-84.1) 22.7 (0.9-89.9) 
     0-14 15 (32.6%) 35 (38.9%) 
     >14 31 (67.4%) 55 (61.1%) 
PIK3CA mutation status *   
     Wildtype 27 (58.7%) 53 (58.9%) 
     Mutation 19 (41.3%) 30 (33.3%) 
          Kinase-domain mutation 14 (30.4%) 15 (16.7%) 
          Helical-domain mutation 5 (10.9%) 14 (15.6%) 
   
Table 3  Patient demographics and tumour characteristics at baseline; Kinase-domain 
mutations include H1047R/Y, H1048R, G1049D/R; Helical-domain mutations include E524K, 
E545K; * All patients in the anastrozole arm were evaluable for PIK3CA mutations analysis; 
7 patients in the Pictilisib and anastrozole arm were not available for PIK3CA NGS analysis; 




Figure 9 demonstrates the individual Ki67 results for the two separate assessments. 
There was high concordance between both readers. The mean (median) difference 
between the 2 analyses was 3.90% (3.06%) for the baseline assessment and 2.63% 
(1.72%) for the end of treatment analysis, respectively. When using a 14% cutoff for 
Ki-67, the Cohen’s kappa value (Cohen, 1960) at baseline was 0.77 and at end of 











Tumour Ki67 expression decreased in the 93.4% of patients over the course of the 
study treatment from baseline to day 15 (Figure 10a, b); in 9 patients Ki67 expression 
numerically increased, including 5 patients in the anastrozole group (10.9 of all 
patients treated with anastrozole) and 4 patients in the combination group (4.4%). In 
4 of the patients with a numerical increase in Ki67 expression, the pre-treatment and 
EOT Ki67 remained under 10% and absolute changes in expression were low. More 
patients in the combination group (87.8%) had an EOT Ki67 expression of <10% 
compared to anastrozole alone (71.7%). 
Mean percentage suppression of Ki67 was 82.5% (95% CI, 78.3%-85.8%) for 
anastrozole plus pictilisib treated patients and 70.7% (61.0%-78.0%) for anastrozole 
treated patients (Table 4; Figure 10 A). The ratio (combination/anastrozole) of mean 
Ki67 suppression was 0.60 (0.58-0.85; p=0·01). The geometric mean end of treatment 
Ki67 expression was 6.3% (3.7%-8.8%) for anastrozole plus pictilisib and 9.5% (6.3%-
12.8%) for anastrozole alone (p=0.02). The EOT response rate RKi67-Day15 was 
higher with the combination 83.3% (76.8%-90.9%) compared to anastrozole alone 







































Figure 10: Individual Ki67 changes from baseline to Day 15 and Anti-proliferative response 
to study treatment; a) Individual changes in percentage Ki67 expression from baseline to 
Day 15; the number and percentage of patients achieving an end of treatment (EOT) Ki67 
score of >10% or ≤10% are provided for each group; b) Individual relative Ki67 suppression 
sorted from low to high; relative Ki67 Suppression is defined as Ln(Ki67Day15) – 
Ln(Ki67baseline); results are displayed on their original scale by back transformation. c) 
anti-proliferative response expressed as the geometric mean Ki67 suppression in from 
baseline to day 15; error bars indicate 95% CI; d) anti-proliferative response at day 15 
compared with baseline. The cumulative proportion (by percentage) of patients who had 
tumours with percentage positive Ki67 (expressed as the natural logarithm) less than the 







(n = 46) 
Pictilisib plus 
Anastrozole                







Ki67 suppression                              
[% (95% CI)] 
70.7%               
(61.0%-78.0%) 
82.5%           
(78.3%-85.8%) 
0.60 1              
(0.58-0.85)  
p=0.01 
The geometric mean 
EOT Ki67 expression           
[% (95% CI)] 
9.5%                     
(6.3%-12.8%) 
6.3%                  
(3.7%-8.8%) 
0.66 1               
(0.58-0.69) 
p=0.02 
RΔKi67 response rate                       
[% (95% CI)] 
69.6%                   
(58.0%-81.1%) 
81.1%                 
(74.2%-88.0%) 




rate     [% (95% CI)] 
65.2%                
(53.3%-77.1%) 
83.3%        
(76.8%-90.9%) 
1.36                   
(1.05-1.55) 
p=0·02 
Table 4  Anti-proliferative response to anastrozole or anastrozole plus pictilisib; geometric 
mean Ki67 suppression is defined as Ln(Ki67Day15) - Ln(Ki67baseline); the ratio 
(combination/ anastrozole) of geometric mean Ki67 suppression is provided with 95% CI. 
Geometric mean end-of-treatment (EOT) Ki67 expression is defined as Ln(Ki67Day15)]; 
individual EOT anti-proliferative response RKi67-Day15 is defined as Ln(Ki67Day15) ≤2; 
individual anti-proliferative response RΔKi67 is defined as a ≥50% fall in Ki67 expression 
between baseline and Day 15. 1 Geometric mean ratio of Ki67 proportional changes 




2     Effect of Study Treatment on Tumour Cell Apoptosis  
Overall, the rate of apoptosis at baseline and end of treatment was extremely low 
throughout the trial limiting the ability to assess possible differences between 
treatment groups (Table 5).  
In contrast to previous reports, we were unable to demonstrate a clear correlation 
between Ki67 and apoptosis (Figure 11), We analysed the growth index defined as 
percent Ki67-expresion divided by percent Caspase-3 expression (Table 6). There was 
a greater suppression in the growth index in the combination arm (75.2%) compared 
to anastrozole alone 55.9% (Figure 12), but was not statistically significant.   
 
 Anastrozole 
(n = 33) 
Pictilisib plus 
Anastrozole                








Casp-3 expression                           
[% (95% CI)] 
0.14%                     
(0.10%-0.18%) 




mean EOT Casp-3 
expression           
[% (95% CI)] 
0.14%                     
(0.11%-0.18%) 
0.14%                  
(0.10%-0.19%) 
NS NS 
Table 5 Induction of apoptosis with anastrozole or anastrozole plus pictilisib; geometric 
mean Ki67 suppression is defined as Ln(Ki67Day15) - Ln(Ki67baseline); the ratio 
(combination/ anastrozole) of geometric mean Ki67 suppression is provided with 95% CI. 
Geometric mean end-of-treatment (EOT) Ki67 expression is defined as Ln(Ki67Day15)]; 
individual EOT anti-proliferative response RKi67-Day15 is defined as Ln(Ki67Day15) ≤2; 
individual anti-proliferative response RΔKi67 is defined as a ≥50% fall in Ki67 expression 







Figure 11: Relationship between Ki67(%) and apoptosis (%) before and after 2 weeks of 





(n = 33) 
Pictilisib plus 
Anastrozole                






The geometric mean 
baseline growth index                    
[% (95% CI)] 
433.2                    
(190.0-676.4) 
635.5                  
(381.2-889.8) 
NS NS 
The geometric mean 
EOT growth index                    
[% (95% CI)] 
190.9                     
(71.5-310.3) 
157.5                  
(93.0-222.1) 
NS NS 
The mean relative 
growth index 
suppression             [% 
(95% CI)] 
55.9                    
(4.4-270.7) 
75.2                    
(25.3-191.8) 
NS NS 
Table 6 Treatment-associated change in growth index (GI), defined as Ki67[%]/Caspase-
3[%], with anastrozole or anastrozole plus pictilisib 
 
 





3     Effect of study treatment in subgroups defined by PIK3CA mutations, 
Luminal A/B subtypes and baseline Ki67 scores  
 
PIK3CA mutation subtypes and response to study treatment:  
Three major hotspots of mutations of the PIK3CA gene have been described; these 
are concentrated in the helical (E542K and E545K) and kinase (H1047R) domains, 
accounting to approximately 90% of all PIK3CA mutations (Ellis et al., 2010). In the 
OPPORTUNE trial, we tested for PIK3CA mutations using NGS. At least one PIK3CA 
mutation was detected in 49 tumours (36.0%), including 19 helical domain and 29 
kinase domain mutations. There was no significant correlation between PIK3CA 
mutation and added activity of pictilisib (Table 7); the ratio 
(combination/anastrozole) of geometric mean Ki67 proportional change was 0.63 
(0.39–1.0; p=0.05) for patients with PIK3CA-wildtype tumours and 0.72 (0.46–1.15; 
p=0.12) for patients with PIK3CA-mutated tumours.  
Interestingly, a significant interaction was observed between PIK3CA mutation 
subtypes [helical domain mutations (HD), kinase domain mutations (KD), wildtype 
(WT)] and mean Ki67 suppression (Figure 13); the combination/anastrozole 
geometric mean ratio of Ki67 suppression was 0.48 (0.27-0.84; p=0.02) for patients 
with HD mutations and 0.63 (0.39–1.0; p=0.05) for patients with PIK3Ca WT, 
compared to 1.17 (0.57–2.41; p=0.64) for patients with KD mutations. This was 
largely due to patients with HD mutations showing a particularly poor response to 
anastrozole alone [mean Ki67 suppression 53.9% (9.5%-76.5%)], that was reversed 
by the addition of pictilisib [mean Ki67 suppression 78.1% (71.0%-83.4%)].  
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On the other hand, patients with KD mutations responded well to anastrozole alone 
[mean Ki67 suppression 77.7% (57.0%-88.4%)] and showed no benefit from the 





(n = 46) 
Pictilisib plus 
Anastrozole                






Ki67 suppression [% 
(95% CI)] 
    
PIK3Ca WT 
69.9                  
(45.7 – 80.2) 
81.1                   
(75.2 – 85.6) 




53.9                              
(9.5 - 76.5) 
78.0              
(71.0 – 83.3) 
0.48                 
(0.27-0.84) 
0.02 
KD mutations  
77.7                     
(57.0-88.4) 
73.9                
(59.8 – 83.0) 
1.17                 
(0.57–2.41 
0.64 
RKi67-Day15 response rate     
[% (95% CI)] 
     
PIK3Ca WT 
59.3                     
(42.8-75.7) 
84.9                 
(76.6-93.2) 




75.0                      
(16.2-133.8)            
84.6             
(66.1-103.3) 
1.13                      
(0.68 -1.88) 
0.58 
KD mutations  
81.8                 
(59.7-103.9) 
78.6             
(58.4-98.7) 
0.96                       
(0.69-1.33) 
0.62 
Table 7 PIK3CA status and anti-proliferative response to anastrozole or anastrozole plus 
pictilisib; geometric mean Ki67 suppression is defined as Ln(Ki67Day15) - Ln(Ki67baseline); 
the ratio (combination/ anastrozole) of geometric mean Ki67 suppression is provided with 







Figure 13: Anti-proliferative response to study treatment by PIK3CA mutation status; e9: 
exon 9 domain mutations (helical domain); e20: exon 20 domain mutations (kinase domain) 
 
Further NGS analysis demonstrated a range of somatic mutations in keeping with the 
expected mutational landscape of ER-positive early breast cancer. Figure 14 shows 
an overview of the somatic variants for each treatment group, divided by response 
to treatment. There was no specific mutational pattern associated with response to 
anastrozole or anastrozole plus pictilisib, when looking at the number of mutations 









Figure 14: A) Somatic variant analysis and response to anastrozole  or anastrozole/pictilisib. 
B) Forest plots showing the log odds ratio indicate there is no correlation between the top 
genes and response to treatment. 
 
PAM50 Luminal Status and treatment response:  
NanoString PAM50 analysis was performed in a subset of patients (n=53) to assess 
luminal status. PAM50 results analysis showed that patients with Luminal B tumours 
had a significantly higher anti-proliferative response with the combination of 
anastrozole plus pictilisib compared to anastrozole alone [geometric mean Ki67 
suppression, 86.5% versus 63.6%; ratio (combination/anastrozole) 0.37 (0.18-0.76; 
p=0.008)], whereas adding pictilisib to anastrozole had no apparent benefit for 





Baseline Ki67 expression, PR, tumour grade and treatment response: 
As it had been hypothesised that luminal B biology could be a determinant of 
suboptimal response to endocrine therapy alone and potentially therefore define a 
subgroup that might derive an increased benefit from combination therapy with 
pictilisib and anastrozole, the impact of a number of baseline characteristics that 
have been linked with luminal B phenotype were explored. These include baseline 
Ki67 expression, PR expression and tumour grade.  
In an analysis involving all evaluable patients (n=136), luminal status was defined by 
baseline Ki67 expression in accordance to the St Gallen criteria (Coates et al., 2015) 
using a Ki67 expression of 14% as the cut-off between luminal A and luminal B. In 
contrast to the PAM50 analysis (Figure 15a), patients with Luminal A status (n=50) 
defined as baseline Ki67 of <14% had a significant benefit of the combination of 
anastrozole plus pictilisib compared to anastrozole alone [geometric mean Ki67 
suppression, 74.1% versus 43.4%; ratio (combination/anastrozole) 0.46 (0.25 – 0.85); 
p=0.02)] (Figure 15b). In patients with Luminal B tumours (n=86), defined as Ki67 
>14%, geometric mean Ki67 suppression was 78.7% in the anastrozole alone group 
and 86.3% for patients treated with anastrozole plus pictilisib [ratio, 0.64 (0.43 – 
0.97); p=0.04].  
Using a Ki67 cut-off of 20%, mean geometric Ki67 suppression for Luminal A tumours 
was 61.6% in the anastrozole alone group and 77.6% for patients treated with 
anastrozole plus pictilisib [ratio, 0.58 (0.25 – 0.97); p=0.04]. For Luminal B tumours, 




alone and 86.7% for patients treated with anastrozole plus pictilisib [ratio, 0.59 (0.36 
- 0.96); p=0.04]. 
 
 
Figure 15: Anti-proliferative response to study treatment; A) anti-proliferative response by 
Luminal subtype defined by PAM50; B) anti-proliferative response by Luminal subtype 
defined by baseline Ki67 expression (cut-off 14%) 
 
PR receptor status was available in all 136 patients; the majority of tumours were 
classified as PR positive (84.6%), defined by an Allred score of 3 or higher (Figure 
16A). Only 21 tumours were PR negative (15.4%). The addition of pictilisib increased 
the anti-proliferative response in both subsets with a slightly more pronounced 
benefit in patients with PR negative tumours. In PR-positive tumours, the geometric 
mean Ki67 suppression was 72.1% with anastrozole compared to 81.7% with the 




Ki67 suppression was 66.7% with anastrozole compared to 88.4% with the 
combination [0.35 (0.14–0.87); p=0.03] (Figure 16a). 
Tumour grade was available for 135 patients; the majority of tumours were classified 
as Grade 1 or Grade 2 (n=115; 85.2%) with the remaining 21 tumours classified as 
Grade 3 (15.6%). Tumour grade was a strong predictor of response to anastrozole 
alone with a mean geometric Ki67 suppression of 73.2% (61.0%-81.6%) in patients 
with Grade 1 or Grade 2 tumours compared to 50% (19.4%-69.0%) in patients with 
G3 tumours (Figure 16B). In contrast, patients responded to anastrozole plus pictilisib 
irrespective of the tumour grade with a mean geometric Ki67 suppression of 80.4% 
(74.8%-84.8%) for patients with Grade 1 or Grade 2 tumours and 90.3% (78.8%-
95.5%) for patients with Grade 3 tumours. 
 
 





Multivariate linear regression analysis confirmed a significant interaction between 
treatment effect and molecular subtype by PAM50 (p=0.03), supporting the 
observation that the combination treatment is more effective than anastrozole alone 
for patients with Luminal B tumours irrespective of PR status or the baseline Ki67 
expression. However, patients with PR-negative Luminal B cancers showed the 
greatest anti-proliferative effect from combination treatment (ratio=0.12). 
Furthermore, combined treatment also appeared to be more effective in PR-negative 





4     PI3K kinase pathway activation and treatment benefit  
To further assess the potential interaction of activation of the PI3K pathway and 
study treatment, we performed analysis of changes in gene/protein expression and 
phosphorylation of selected signalling markers. 
Two gene expression signatures (GS) were calculated at baseline and at the end of 
treatment using the Nanostring gene expression data. The GS data were correlated 
with baseline characteristics and response to anastrozole and the combination 
therapy, respectively. The PIK3CA mutation associated GS (Loi et al., 2010) has 
previously been shown to negatively correlate with proliferation, AKT/mTOR 
activation and PTEN loss and strongly positively correlated with ESR1 and better 
outcome in ER-positive breast cancer. O’Brien et al identified a PIK3 inhibitor 
sensitivity GS, based on a number of genes that are differentially expressed between 
sensitive and resistant breast cancer cell lines; the PIK3 inhibitor sensitivity GS 
(O’Brien et al., 2010) has been shown to correlate with activation of the PI3K pathway 
and can be used to characterise patients who are sensitive to PI3K inhibition.  
The baseline PIK3 inhibitor sensitivity GS (O’Brien) score was associated with higher 
proliferation and Luminal B phenotype (Figure 17a). Post-treatment PIK3 inhibitor 
sensitivity GS (O’Brien) scores were significantly down-regulated in both arms, 
consistent with an attenuation of the flux through the PI3K pathway (Figure 17b).  
In contrast, we observed no relevant modulation of the PIK3CA mutation-associated 
GS (Loi) with study treatment (Figure 17c). The PIK3CA mutation-associated GS (Loi) 






Figure 17: PI3K mutation and PI3K inhibitor sensitivity gene signatures: a) association of baseline PIK3 inhibitor sensitivity GS (O’Brien) score and Luminal B 
phenotype; b) down-regulation of post-treatment PIK3 inhibitor sensitivity GS (O’Brien) scores in both treatment arms; c) post-treatment PIK3CA mutation-
associated GS (Loi) in both treatment groups; A=anastrazole only, C=combination with pictilisib. 
 
A) B) C) 
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5     Treatment-induced changes in gene/protein expression and 
phosphorylation  
 
Treatment-induced changes in protein expression and phosphorylation and gene 
expression were evaluated in subsets of patients, using RPPA (n=32) and Nanostring 
analysis (n=64). Figure 18a and b provide an overview of differentially expressed 
genes between pre- and post-treatment samples in the anastrozole and anastrozole 
and pictilisib groups, respectively. The top ten genes differentially expressed in each 
arm of the treatment groups are shown in Table 8. The top differentially expressed 
canonical pathways in the anastrozole group included cyclines and cell cycle 
regulation, oestrogen-dependent signalling and gene expression, ATM signalling, 
mitotic kinases, and aryl hydrocarbon receptor signalling. There was substantial 
upregulation of a number genes associated with the immune system, whereas many 
of the most downregulated genes were involved in cell cycle control.  
In the anastrozole plus pictilisib group, top upregulated canonical pathways included 
pancreatic adenocarcinoma signalling, aryl hydrocarbon receptor signalling, IL-8 
signalling, bladder cancer signalling and GADD45 signalling. There was also 
substantial upregulation of genes associated with the immune system and 





Figure 18 Differentially-expressed genes between pre- and post-treatment samples in the 



















Table 8 The top 10 gene transcripts overexpressed and repressed in A) anaztrozole and B) 
combination treated patients. Only genes that with p-value <0.05 are included. 
 
ER target genes: Previous data suggested that single agent PI3K inhibition up-
regulates expression of ER target genes in vivo and in vitro (Bosch et al., 2015). In a 
preclinical study, treatment with the PI3K inhibitor BYL719 (p110a) was associated 
with substantially increased expression of ER-target genes. Furthermore, treatment 
with BYL719 upregulated ESR1 expression in tumour samples of treated patients.  
Log2 fold change std error (log2) P-value probe.ID
RAB7B-mRNA 3.6 0.622 1.98E-06 NM_177403.3:1485
Fos-mRNA 3.45 1.01 0.0018 NM_005252.2:1475
TWIST1-mRNA 3.2 0.606 8.81E-06 NM_000474.3:35
SRC2-mRNA 2.98 0.628 4.17E-05 NM_005248.1:375
eif4b-mRNA 2.63 0.676 0.000471 NM_001417.4:295
CCL4L1-mRNA 2.55 0.452 3.07E-06 NM_001001435.2:11
CD68-mRNA 2.51 0.629 0.000366 NM_001251.2:1140
RPS6-mRNA 2.45 0.593 0.000241 NM_001010.2:171
FOXA1-mRNA 2.45 0.675 0.000957 NM_004496.2:2465
CCL18-mRNA 2.41 1.05 0.0286 NM_002988.2:585
MAD2L1-mRNA -1.09 0.433 0.0165 NM_002358.3:182
ORC6L-mRNA -1.1 0.457 0.0225 NM_014321.2:582
CDC20-mRNA -1.1 0.508 0.0382 NM_001255.2:430
UBE2T-mRNA -1.14 0.381 0.00518 NM_014176.3:595
E2F1-mRNA -1.26 0.509 0.0187 NM_005225.1:935
CCND1-mRNA -1.28 0.531 0.0217 NM_053056.2:690
TRIP13-mRNA -1.47 0.494 0.00556 NM_004237.2:450
DTL-mRNA -2.01 0.454 0.000106 NM_016448.2:380
FGFR3-mRNA -2.04 0.624 0.00263 NM_022965.2:3170
GREB1-mRNA -2.29 0.564 0.000289 NM_014668.3:1360
Log2 fold change std error (log2) P-value probe.ID
Fos-mRNA 3.86 0.655 8.32E-08 NM_005252.2:1475
Jun-mRNA 3.45 0.44 1.62E-11 NM_002228.3:140
MAML2-mRNA 2.51 0.448 2.99E-07 NM_032427.1:4125
CD11c-mRNA 2.31 0.445 1.61E-06 NM_000887.3:700
Decorin-mRNA 2.12 0.439 6.88E-06 NM_001920.3:420
ALDH1A1-mRNA 2.08 0.441 1.02E-05 NM_000689.4:276
IRS2-mRNA 2.02 0.389 1.57E-06 NM_003749.2:775
MYC-mRNA 1.99 0.45 3.03E-05 NM_002467.3:1610
ALDH1A3-mRNA 1.97 0.426 1.48E-05 NM_000693.2:2280
ETBR-mRNA 1.94 0.402 6.84E-06 NM_003991.2:560
S100A14-mRNA -2.34 0.599 2.00E-04 NM_020672.1:460
FGFR3-mRNA -2.38 0.6 0.000157 NM_022965.2:3170
Pfs2-mRNA -2.76 0.447 2.62E-08 NM_016095.2:990
GFRA1-mRNA -2.82 0.651 4.22E-05 NM_005264.4:1895
PGR-mRNA -2.89 0.518 3.03E-07 NM_000926.2:3165
UBE2C-mRNA -2.92 0.401 2.10E-10 NM_181803.1:269
GREB1-mRNA -3.16 0.391 5.54E-12 NM_014668.3:1360
CENPF-mRNA -3.48 0.419 2.11E-12 NM_016343.3:5822
BIRC5-mRNA -3.51 0.43 3.96E-12 NM_001168.2:1215





We therefore investigated the effect of treatment with pictilisib and anastrozole on 
ER target genes, using Nanostring gene expression analysis. As illustrated in Figure 
19 there was a significant treatment-associated reduction in the expression of ER 
target genes such as GREB1 or PR. No differences were observed between the 2 study 





Figure 19: Treatment-induced changes in expression of ER target genes PR and GREB1; A, 
anastrozole alone; C, combination. 
 
PI3K pathway and cell cycle. RPPA analysis focused on key genes involved in the 
activation of the PI3K pathway and cell cycle. Baseline protein expression and 
phosphorylation was comparable between both groups. There was substantial 
downregulation of cell cycle genes in both arms, associated with endocrine therapy. 
Although total AKT levels seemed to increase more in anastrozole-treated patients, 
end-of-treatment Phospho-AKT levels were similar in both treatment groups. 




was comparable. RPPA levels suggest a possible increase in Phospho-Raptor levels 
with anastrozole but pS6 levels or p4E-BP1 levels were similar between both arms 
(Figure 20; Figure 21). Overall, the end-of-treatment profiles as well as the treatment-
associated changes (Figure 21) were largely comparable between both groups, 
suggesting a dominant anti-oestrogen effect. The effects on Cyclin D1 were more 
pronounced with the combination in keeping with the more substantial anti-
proliferative effect as per Ki67 analysis.  
Gene expression analysis in the anastrozole group demonstrated upregulation of 
genes involved in cell cycle arrest such as p21. In the combination group, gene 
expression analysis also demonstrated up-regulation of the PI3K regulated genes 












Figure 20: RPPA analysis of Phospho-AKT levels (a) and pS6 levels (b) after treatment with 
anastrozole or combination therapy; treatment-associated upregulation of PIK3CA-





















Figure 21: RPPA analysis focusing on key genes involved in the activation of the PI3K pathway and cell cycle. A) Mean end-of-treatment RPPA expression in 





6     Effects of PI3K inhibition on the tumour microenvironment and 
immune system 
 
There is substantial evidence that E2 and/or ER signalling regulates the development 
and function of dendritic cells (Kovats, 2012), B and T lymphocytes, NK cells, 
monocytes and macrophages (Cunningham and Gilkeson, 2011; Straub, 2007). In 
addition, there is discussion around the role of PI3K signalling and the tumour 
microenvironment. There are examples of increasing nonclinical and clinical data 
suggesting a correlation between PTEN loss and impaired anti-tumour immune 
response, including reduced CD8 T-cell infiltration and reduced efficacy of anti-PD1 
therapy. Furthermore, nonclinical studies reveal synergistic anti-tumour responses 
when combining PI3K/AKT pathway inhibition and PD-L1/PD-1 axis blockade (Peng et 
al., 2016). In addition, PI3K or AKT inhibitors may restore and enhance physiological 
functionalities of T cells in the tumour microenvironment and enhance expansion of 
tumour-specific lymphocytes with memory cell phenotype (Crompton et al., 2015). 
Treatment with AKT inhibitors has also been shown to promote the development of 
memory T cells over effector T cells (Gubser et al., 2013; Xue et al., 2015). Based on 
these findings, we therefore performed gene expression analysis to assess the impact 
of anastrozole and the combination therapy on the tumour microenvironment and 
immune system. The major gene transcript representative for specific immune cells 
were examined if there were any changes. Analysis of pre and post treatment 
samples showed that a 2-week treatment of anastrozole and anastrozole plus 
pictilisib have a modest impact on the tumour immune microenvironment; the 
observed effects differed between the two treatment groups (Figure 22a). Whilst in 
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patients treated with anastrozole a modest increase in CD8A transcript was 
observed, combination therapy was associated with a modest increase in CD68, CD4 
and CD8A transcripts. In the tumour samples from patients that received 
combination therapy, there was an increase in the expression of markers indicative 
for macrophages, CD4 and CD8+ cell recruitment, as well as increase of 
immunosuppressive molecules such as PD-L1, PD-L2 and IDO (Figure 22b). No 
significant increase in FOXP3+ effector cells was observed in either arm. Study 
treatment had a minimal impact on Teff and Treg signatures and on T-cell 
immunosuppressive signature but a modest impact on APC immunosuppressive 










































Figure 22 a) Impact on markers of immune cell populations (CD68, CD4, CD8A) in the post-
treatment samples; b) Treatment effect on Teff and Treg signatures; c) APC 






Chapter 5 Discussion 
The OPPORTUNE trial was designed to evaluate whether the addition of the PI3K 
inhibitor pictilisib to endocrine therapy with anastrozole can increase the effects on 
tumour cell proliferation or apoptosis, to identify potential predictors of sensitivity 
to PI3K‐inhibition, and to study the effects of combined endocrine and PI3K‐inhibitor 
therapy on breast cancer biology. 
The primary endpoint of the study was to assess treatment-associated changes in the 
expression of the proliferation marker Ki67 after two weeks of preoperative 
endocrine therapy. Short-term, preoperative studies of 2-week therapy are a 
validated strategy to evaluate the impact of targeted therapies alongside endocrine 
agents, using the nuclear proliferation marker Ki67 as an intermediate surrogate 
endpoint of treatment benefit (Dowsett et al., 2007, 2005; Ellis et al., 2008; Hadad et 
al., 2011; Macaskill et al., 2011; Polychronis et al., 2005). The study required each site 
to fix each sample for more than 6 hours and embed the tumour samples locally 
before being assessed at a central site. Due to the nature of the multi-center trial, it 
was not possible to remove any variation in the pre-analytical steps, but the variation 
is removed by cutting, staining and assessing at a central site (Yerushalmi et al., 
2010). In this study, Ki67 expression was assessed centrally by IHC according to 
previously established and validated criteria and expression was recorded 
independently by two investigators, who were blinded as to treatment allocation and 
each other’s assessment (Prof Sarah Pinder, Dr Louise Lim). We were able to 
demonstrate high concordance between both Ki67 assessments. The mean (median) 
difference between the 2 analyses was 3.90% (3.06%) for the baseline assessment 
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and 2.63% (1.72%) for the end of treatment analysis, respectively. The Cohen’s kappa 
value represents the degree of accuracy and reliability in statistical classification. 
When using the defined 14% cut-off, the kappa value of 0.77 found substantial 
agreement between the independent scorers. The cut-off value for Ki67 is currently 
debatable despite the number of published studies reporting significant results, 
ranging from 1-30% (Dowsett et al., 2011). We have decided on 14% for Ki-67 is as 
recommended by the St Gallen panel to differentiate between low proliferation 
(<14%) and high proliferation tumours  (Goldhirsch et al., 2011). As defined in the 
statistical analysis plan, all endpoint analyses were performed using the geometric 
mean of the two Ki67 assessments. Our results demonstrate that adding pictilisib to 
anastrozole significantly increased the anti-proliferative response compared with 
two-week preoperative anastrozole treatment in previously untreated patients with 
ER-positive invasive breast cancer as measured by suppression of Ki67 expression, 
confirming the primary trial hypothesis. As previously established, we applied 
different analytical methods to assess the treatment-associated changes in Ki67 
expression. Mean Ki67 suppression was selected as the primary analysis method in 
keeping with previous pivotal trials in this area. Ki67 suppression was calculated after 
log transformation of Ki67 values, assuming a log normal distribution. Results were 
subsequently back transformed to their original scale. We were able to demonstrate 
a statistically significant reduction in mean percentage suppression of Ki67 from 
70.7% (61.0%-78.0%) for anastrozole treated patients to 82.5% (95% CI, 78.3%-
85.8%) for anastrozole plus pictilisib treated patients, which is an approximately 40% 
increased suppression (ratio, 0.60 0.58-0.85; p=0·01). 
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An alternative method for the Ki67 analysis focused on end of treatment Ki67 
expression. This endpoint is particularly relevant as reduced Ki67 expression after 
two weeks of preoperative endocrine therapy has been associated with an improved 
recurrence-free survival (RFS) in ER positive postmenopausal breast cancer patients 
(Dowsett et al., 2007). In the preoperative IMPACT trial, which evaluated 4 months 
of preoperative therapy with anastrozole, tamoxifen, or anastrozole plus tamoxifen 
in ER-positive, postmenopausal BC patients but also had an early assessment of Ki67 
changes after 2 weeks, the hazard ratio for RFS was 1.95 (95% CI 1.23-3.07) per 2.7-
fold increase of Ki67 expression after two weeks of preoperative endocrine therapy 
(Dowsett et al., 2007). 5-year RFS rates were 85%, 75%, and 60%, respectively, for 
the lowest, middle, and highest tertiles of end of treatment Ki67 expression (Dowsett 
et al., 2007). In contrast, baseline Ki67 expression was only predictive of outcome on 
univariate analysis but not on multivariate analysis (HR 1.09; 95% CI 0.60-1.99), 
suggesting that measurements of tumour cell Ki67 expression after two weeks of 
endocrine treatment may integrate the intrinsic prognostic value of baseline Ki67 
expression measurements and the predictive value of the treatment–determined 
changes in Ki67 expression (Dowsett et al., 2007). Interestingly, the results of the 
IMPACT trial, which demonstrated an increased anti-proliferative response to 
anastrozole compared to tamoxifen or anastrozole plus tamoxifen, were highly 
concordant with the results of the large adjuvant ATAC trial (Arimidex, Tamoxifen, 
Alone or in Combination (ATAC) Trialists’ Group et al., 2008).  
Similar results were obtained in the POETIC phase III trial, which was set up to 
determine whether 2 weeks perioperative aromatase inhibitor (AI) therapy before 
and after surgery improves outcome compared with standard adjuvant therapy alone 
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in postmenopausal women with ER/PR positive invasive breast cancer (Robertson et 
al., 2018). The trial used Ki67 expression as a primary measure of the anti-
proliferative effects of the study treatment and correlated it with long term outcome. 
A total of 4,486 patients were recruited from 130 UK sites over a 5.5-year period. 
Patients with baseline Ki67 expression of <10%, generally had an excellent outlook 
with a 5-year absolute recurrence risk of 4.5% (95% CI, 3.1%-6.6%). More 
importantly, in patients with a baseline KI67 expression of ≥10%, the end of 
treatment Ki67 expression was a strong predictor of long term outcome [HR 2.22 
(95%CI: 1.68, 2.94); p<0.001]. The 5-year absolute recurrence risk was 8.9% (7.2%-
11.0%) for patients with end of treatment Ki67 levels of <10% compared to 19.6% 
(15.9%-24.1%) with end of treatment KI67 expression levels of ≥10%. 
As previously established, we used 2 different ways of analysing end of treatment 
response either through the geometric mean Ki67 expression at the end of study 
treatment (Mean Ki67post) or the EOT response rate RKi67-Day15 defined as the 
natural logarithm of percentage Ki67 positive cells of less than 1 or 1-2 at the end of 
study treatment. Both the geometric mean end of treatment Ki67 suppression and 
the EOT response rate RKi67-Day15 were increased with the combination of 
anastrozole plus pictilisib compared to anastrozole alone, further supporting the 
main hypothesis that the addition of the PI3K inhibitor improves the anti-
proliferative effects of anastrozole. 
The second main hypothesis was whether combining endocrine therapy and PI3K 
inhibitors can lead to an increase in tumour cell apoptosis. This was supported by 
preclinical data demonstrating that oestrogen can suppress apoptosis induced by 
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PI3K inhibition in ER-positive breast cancer, suggesting independent PI3K- and E2-
dependent cell survival mechanisms. As a result, combination of endocrine therapy 
and PI3K inhibitors can lead to synthetic lethality with substantially increased 
apoptosis compared to single-agent therapy. We therefore evaluated changes in 
tumour cell apoptosis, as measured by Caspase 3 expression in pre and post-
treatment tumour samples, between both treatment groups. As for Ki67, caspase-3 
expression was assessed centrally by IHC according to previously established and 
validated methods and expression was recorded independently by two investigators 
who were blinded as to treatment allocation and each other’s assessment (Prof Sarah 
Pinder, Dr Louise Lim). We were again able to demonstrate high concordance 
between both caspase-3 assessments.  
In keeping with other studies in this field, the rate of apoptosis was low in this trial 
with the majority of tumour samples containing less than 1% apoptotic cells and a 
geometric mean expression of 0.15%. There was no clear evidence of a treatment-
associated increase in Caspase-3 expression but the results have to be interpreted 
with caution, as the low rate of apoptosis together with the strong positive 
correlation between Ki67 and apoptosis scores, found in this and other trials 
(Dowsett et al., 2007), could mask an effect of PI3K inhibition on apoptosis as 
observed in preclinical studies (Crowder et al., 2009). Other groups have therefore 
introduced growth index, defined as percent Ki67-expresion divided by percent 
Caspase-3 expression. Using this method, we were able to describe a greater 
suppression in the growth index in the combination arm (75.2%) compared to 
anastrozole alone 55.9%, although this was not statistically significant.  
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The third main objective of this thesis was to investigate the interaction between the 
treatment benefit of pictilisib and/or anastrozole and mutations of PIK3CA, the gene 
encoding the catalytic PI3K subunit p110α, the target of pictilisib. Three major 
hotspots of mutations of the PIK3CA gene have been described; these are 
concentrated in the helical (E542K and E545K) and kinase (H1047R) domains, 
accounting to approximately 90% of all PIK3CA mutations. In keeping with other 
series in ER-positive primary breast cancer [4,8], 36% of the tumours in our study 
carried at least mutation in the PIK3CA gene, 98% of these in one of the three major 
hotspots in the helical (E542K and E545K) and kinase (H1047R) domains. 
Taking all types of PIK3CA mutations together, there was no association between 
overall PIK3CA mutation status and anti-proliferative response for anastrozole alone, 
in keeping with other studies suggesting that the presence of PIK3CA mutations has 
limited impact on the effect of preoperative anastrozole therapy in patients with 
primary, ER-positive breast cancer (Krop et al., 2016; López-Knowles et al., 2014; Ma 
et al., 2017). There was also no correlation between overall PIK3CA mutation status 
and added activity of pictilisib with a ratio of geometric mean Ki67 proportional 
change of 0.63 (0.39–1.0) for patients with PIK3CA-wildtype tumours and 0.72 (0.46–
1.15) for patients with PIK3CA-mutated tumours. This is consistent with results from 
trials of pictilisib or the mTOR inhibitor everolimus in pre-treated, metastatic breast 
cancer, where patients derived benefit from everolimus or pictilisib regardless of 
their tumour PIK3CA genotype (Hortobagyi et al., 2016a; Krop et al., 2016; Treilleux 
et al., 2015). However, recent trials with more specific PI3K inhibitors (α-specific or 
β-sparing), have demonstrated an increased benefit in patients with PIK3CA mutated 
tumours (SOLAR1, SANDPIPER) (André et al., 2019; Baselga et al., 2018). This might 
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be down to more profound target inhibition in the tumour which might be achievable 
due to the improved efficacy/tolerability ratio associated with the lower degree of β-
inhibition which has been associated with driving toxicity. 
Interestingly, we found a significant interaction between PIK3CA mutation subtypes 
and Ki67 suppression. Whilst patients with helical domain mutations [ratio, 0.48 
(0.27-0.84; p=0.02] or PIK3CA wildtype status [ration, 0.63 (0.39–1.0; p=0.05] 
demonstrated a substantial relative benefit from the addition of pictilisib, there was 
not clear additional effect of pictilisib in tumours with KD mutations [ratio, 1.17 
(0.57–2.41; p=0.64]. This was largely due to patients with HD mutations showing a 
particularly poor response to anastrozole alone [mean Ki67 suppression 53.9% (9.5%-
76.5%)], that was reversed by the addition of pictilisib [mean Ki67 suppression, 78.1% 
(71.0%-83.4%)], whereas patients with KD mutations responded well to anastrozole 
alone [mean Ki67 suppression 77.7% (57.0%-88.4%)] and showed no benefit from the 
addition of pictilisib [mean Ki67 suppression 73.9% (59.8%-83.0%)]. A similar 
observation was reported from a neoadjuvant trial of the mTOR inhibitor everolimus 
and letrozole in ER-positive breast cancer, in which exon 9 mutations seemed to be 
associated with an increased benefit of mTOR inhibition relative to exon 20 
mutations (Baselga et al., 2009) and this may merit testing in future studies of early 
breast cancer. 
PTEN expression was not associated with benefit of the combination therapy and 
also did not add significantly to PIK3CA mutations as determinant of PI3K inhibitor 
benefit. As expected being associated with PIK3CA mutations rather than PI3K 
pathway activation, the Loi GS did not change significantly with study treatment and 
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was not predictive of a treatment-associated change in Ki67 expression in either 
treatment arm. On the other hand, the O’Brien GS, which was developed based on a 
number of genes that are differentially expressed between sensitive and resistant 
breast cancer cell lines, was significantly down-regulated with both study treatments, 
consistent with an attenuation of the flux through the PI3K pathway. It was also 
inversely associated with Ki67 suppression in the anastrozole arm, suggesting it 
might be useful for characterising patients with partial endocrine resistance. 
As there is increasing evidence that luminal B biology is a determinant of suboptimal 
response to endocrine therapy alone, it was hypothesized that the intrinsic subtype 
could potentially define a subgroup that might derive an increased benefit from 
combination therapy with pictilisib and anastrozole. We therefore explored the 
possible interaction between intrinsic subtypes defined by NanoString PAM50 
analysis and anti-proliferative response in a subgroup of tumours (n=53) with 
available pre- and posttreatment RNA. Additional analyses were completed on the 
entire study population using alternative markers that have been associated with the 
luminal B phenotype including baseline Ki67 expression, PR expression and tumour 
grade.  
In keeping with our hypothesis, PAM50 analysis showed that patients with Luminal B 
tumours had a significantly higher anti-proliferative response with combination 
treatment compared to anastrozole alone [mean Ki67 suppression, 86.5% versus 
63.6%; ratio 0.37 (0.18-0.76; p=0.008)], whereas adding pictilisib to anastrozole had 
no apparent benefit for Luminal A tumours (ratio, 1.01; p=0.98). It is unclear whether 
this result is more a reflection of the fact that luminal B tumours are partially 
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endocrine resistant compared to the highly endocrine sensitive luminal A tumours, 
than a true differential effect of PI3K inhibitors in the respective subtypes.  
Defining luminal A and B status through baseline Ki67 expression in accordance with 
the St Gallen criteria (using a Ki67 cut-off of 14%) provided somewhat contradictory 
results, demonstrating a significant benefit of combination therapy in patients with 
Luminal A and Luminal B tumours, using alternative cut-offs of 14% and 20%, 
respectively. However, much of the benefit in Luminal A tumours seems to be driven 
by an unexpectedly low Ki67 suppression with anastrozole alone. This is in contrast 
to other studies (Dowsett et al., 2007). A possible explanation is that the Ki67 
suppression results might be less reliable for patients with low baseline expression 
(<10%) considering the variability in the Ki67 assessment as illustrated in the mean 
difference of 2.6%-3.9% between the 2 analyses. Some trials therefore exclude 
patients with a Ki67 baseline expression of <10%. We explored the possibility of an 
additional analysis, excluding patients with baseline Ki67<10%, but the number were 
too low for achieving reliable results. Of note, mean baseline Ki67 expression was 
15.4% for PAM50 Luminal A and 30.7% for PAM50 Luminal B tumours, with 60% of 
Luminal A tumours showing baseline Ki67 values of >10%, suggesting that this 
analysis might be less likely affected by possible technical limitations in tumours with 
low baseline Ki67 levels.  
Additional, pre-planned, subset analyses suggest that the effects of pictilisib added 
to anastrozole are predominantly seen in patients with PR negative and/or grade 3 
tumours. Multivariate linear regression analysis demonstrated an increased 
treatment effect for the pictilisib containing arm in patients with Luminal B cancers 
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independent of baseline Ki67 expression, suggesting an impact of molecular subtype 
on the response to pictilisib independent of baseline proliferation. Overall, these 
findings are supportive of an association between luminal subtype, insensitivity to 
endocrine therapies and response to treatment with a pan-PI3K inhibitor, which have 
implications for future trial design and therapeutic strategies. 
To further evaluate treatment-induced changes in gene expression and protein 
expression/phosphorylation, we used RPPAs and Nanostring gene expression 
analysis in subsets of patients. All the samples used for the gene expression study 
were serial sections from the same tumour that were assessed for Ki-67. The 
performance of the Nanostring platform has been shown to be comparable when 
using FFPE tissue to snap-frozen (Veldman-Jones et al., 2015). The platform is more 
sensitive than microarrays when investigating samples with potentially degraded 
mRNA, reporting excellent reproducibility and robustness as there is no amplification 
bias in the reaction. The platform hybridises to any mRNA present, producing a direct 
read-out of genes present in the sample (Geiss et al., 2008). The samples used for 
RPPA analysis were smaller as we utilised fresh frozen tissue collected. Although FFPE 
samples can be used for RPPA analysis, the variation of tissue handling at different 
sites warranted that only snap-frozen tissue was used for this analysis (Boellner and 
Becker, 2015). We were able to demonstrate profound down-regulation of ER-
mediated transcription and cell cycle progression. Interestingly, we found no 
differences in the expression of ER target genes between both study arms, suggesting 
that the preclinically observed induction of ER target genes by PI3K inhibition 
requires oestrogen and is therefore not relevant in the context of combined 
endocrine and PI3K inhibitor therapy.  
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RPPA analysis focused on key genes involved in the activation of the PI3K pathway 
and cell cycle. There was substantial downregulation of cell cycle genes in both arms 
but Cyclin D1 levels were more suppressed in the combination arm consistent with 
the more substantial anti-proliferative effect demonstrated in the primary Ki67 
analysis. Surprisingly, there was no discernible differences between both groups in 
the expression and/or phosphorylation of PI3K downstream targets Phospho-AKT, 
pS6 and p4E-BP1. On the other hand, gene expression analysis demonstrated up-
regulation of the PI3K regulated genes IRS2 and PIK3IP1, confirming treatment-
associated pathway inhibition. It remains unclear whether the lack of a clear effect 
on PI3K downstream targets has technical reasons or might instead be reflective of 
the complex biology of the PI3K/AKT pathway. It is well recognised that pAKT levels 
can change rapidly during the processing of tissue samples. In the OPPORTUNE trial, 
we therefore defined strict criteria for rapid processing of tissue samples to minimise 
these effects, but it cannot be excluded that RPPA results have been affected by this. 
 
Previous publications have found that inhibition of PI3K/Akt/mTOR pathways in 
patients can be associated with a higher risk of infection due to immunosuppression 
from the function of the immune system rather than the number of immune cells 
(Rafii et al., 2015). mTOR inhibitors are well known to immune-suppressive. The 
suppression of PI3K should alter the signalling pathways for both effector and 
regulatory cell population, with specific inhibition of PI3K subunits suppressing Treg 
cells (Carnevalli et al., 2018). Thus it would be of interest to determine if how PI3K 
inhibition will alter the transcription of genes associated with immune function.  
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We demonstrated that short-term treatment with pictilisib and/or anastrozole has a 
modest impact on the tumour immune microenvironment. Effects differed between 
the two treatment groups suggesting that PI3K inhibition has additional effect to 
endocrine therapy. Most of these effects were modest and the potential clinical 
implications remain to be determined but the emerging role of immunotherapy in 
breast cancer makes underlines the importance of further studies in this context.  
 
There are few areas where improvements could be made for the future from the data 
presented here. This includes recruiting more patients for each arm to enable in-
depth subset analysis as well as modifying the inclusion criteria so as to include 
patients who are also PR-positive which may benefit more from PI3K-inhibition (Krop 
et al., 2016). Finally, the main drawback of a WOO study is that it only investigates 
short-term effects and thus, the benefits cannot currently be extrapolated for 
patients in the long-term.  
 
In summary, the OPPORTUNE trial is one of the first clinical trials to evaluate PI3K 
inhibitors in early breast cancer. It provided proof-of-concept by demonstrating that 
addition of the PI3K inhibitor pictilisib significantly increased the anti-proliferative 
response to anastrozole in ER-positive early breast cancers. The trial also provided 
important information on the subgroup of patients who might benefit most from 
combined therapy. We showed that PIK3CA mutations were not predictive of 
response to PI3K inhibitors (but highlighted potential differences between the 
mutations subtypes) and provided clinical evidence that Luminal B cancer, PR-
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negative cancers and/or high grade tumours have an increased benefit of PI3K 
inhibition, which is in keeping with preclinical data. These data should guide optimal 
patient selection for future trials and could be critical for the successful clinical 
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